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ABSTRACT
Prolyl oligopeptidase (PREP, EC 3.4.21.26; also known as prolyl endopeptidase, POP, PE,
PO or PEP) cleaves proline-containing small peptides. Despite the fact that it is an abundant
peptidase in the mammalian brain and periphery, the physiological role of PREP remains
still unknown. PREP has received attention since its inhibitors have been shown to improve
learning  and  memory  in  various  animal  models.  These  effects  have  been  associated  with
reduced breakdown and elevated brain levels of neuropeptide substrates of PREP, or with
elevated brain levels of classical neurotransmitters such as acetylcholine (ACh). However,
evidence of the neuropeptide and neurotransmitter modifications in vivo is inconsistent.
The  general  objective  of  this  study  was  to  characterize  the  pharmacokinetic  (PK)  and
pharmacodynamic (PD) properties of two model PREP inhibitors, JTP-4819 and KYP-2047,
in  the  rat,  and to  evaluate  the  potential  of  PREP as  a  central  nervous system (CNS)  drug
target.
In  the  PK  studies,  differences  were  observed  in  the  brain  penetration  properties  between
the model inhibitors. The analysis of brain drug levels and PREP inhibition both revealed
that KYP-2047 could penetrate the brain and reach the intracellular PREP better than JTP-
4819 after a single intraperitoneal dose of 50 μmol/kg. These differences may have been
attributable to the poor cell membrane permeability properties of JTP-4819.
In the PD studies, KYP-2047 (15 μmol/kg i.p.) was shown to alleviate scopolamine-induced
memory impairment in young but not in old rats in the Morris water maze. Potential
mechanisms of actions were investigated in biochemical studies in rats using both KYP-
2047 and JTP-4819. At pharmacologically active brain concentrations, these compounds had
no effect on the levels of substance P, neurotensin, inositol-1,4,5-trisphosphate (IP3) or
dopamine (DA) in the rat brain. In contrast to earlier observations, a significant decrease in
the extracellular striatal ACh levels was observed. The effect on ACh levels did not
correlate with the degree of brain PREP inhibition, indicating that the decline may not be
related to the catalytic activity of PREP. In vitro specificity screening could not identify any
off-targets that could explain the observed effects on ACh levels, but instead confirmed that
the present inhibitors have high selectivity towards PREP.
In conclusion, KYP-2047 had suitable PK characteristics to be used as a pharmacological
tool to study the potential of PREP as a CNS drug target. This study confirmed that PREP
inhibitors have some beneficial effects on memory and learning in rats, but the mechanism
of action remains to be clarified. However, it seems that the cholinergic or DAergic systems
or IP3 are not involved in this process. Furthermore, it is not likely that PREP inhibitors
could modulate extracellular neuropeptide levels in the brain due to the fact that PREP is
located intracellularly and peptide cleavage occurs mainly extracellularly.
National Library of Medical Classification: WL 104, WL 200, QV 38, QU 136, QU 143
Medical Subject Headings: Serine Endopeptidases; Pyrrolidines; Enzyme Inhibitors; Pharmacokinetics;
Pharmacology; Central Nervous System; Brain; Blood-Brain Barrier; Neuropeptides; Neurotransmitter
Agents; Acetylcholine; Dopamine; Inositol 1,4,5-Trisphosphate; Substance P; Neurotensin; Maze Learning;
Memory; Microdialysis; Rats
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TIIVISTELMÄ
Prolyylioligopeptidaasi (PREP, EC 3.4.21.26; myös POP, PE, PO tai PEP) pilkkoo proliinia
sisältäviä pieniä bioaktiivisia peptidejä. Vaikka PREP:ä on runsaasti lähes kaikissa elimissä,
sen fysiologinen merkitys on edelleen epäselvä. PREP on herättänyt kiinnostusta
mahdollisena lääkevaikutuksen kohteena, koska selektiivisten PREP:n estäjien on havaittu
parantavan muistia ja oppimista eri eläimalleissa. PREP:n eston on uskottu vähentävän
PREP:n substraateina toimivien neuropeptidien hajoamista aivoissa. Tämän seurauksena
joko näiden peptidien tai muiden muistiin ja oppimiseen liittyvien välittäjäaineiden, kuten
asetyylikoliiniin (ACh), määrä lisääntyisi aivoissa. Tätä teoriaa ei ole kuitenkaan pystytty
luotettavasti todistamaan in vivo.
Tämän tutkimuksen tavoitteena oli tutkia kahden malliyhdisteen (JTP-4819 ja KYP-2047)
avulla PREP-estäjien farmakokineettisiä (PK) ja farmakodynaamisia (PD) ominaisuuksia
rotalla sekä arvioida keskushermoston PREP:n merkitystä mahdollisena lääkevaikutuksen
kohteena. PK-tutkimuksissa havaittiin eroja malliyhdisteiden aivopenetraatiossa. Rotan
vatsaonteloon (intraperitoneaalisesti; i.p.) annetun kerta-annoksen (50 μmol/kg) jälkeen
suurempi osuus KYP-2047:stä läpäisi veri-aivoesteen, minkä seurauksena aivojen PREP
estyi tehokkaammin kuin JTP-4819:llä. JTP-4819:n pienempi veri-aivoesteen läpäisevyys
johtunee siitä, että se läpäisee solukalvoja huomattavasti huonommin kuin KYP-2047.
Farmakodynaamisissa kokeissa KYP-2047:n (15 μmol/kg i.p.) havaittiin parantavan nuorten
mutta ei vanhojen rottien tilamuistia Morrisin vesisokkelossa. Tämän vaikutuksen
mahdollisia mekanismeja tutkittiin mittaamalla eri välittäjäaineiden aivopitoisuuksia JTP-
4819- tai KYP-2047-käsittelyjen jälkeen. PREP:n esto ei vaikuttanut rotan aivojen substanssi
P-, neurotensiini-, inositoli-1,4,5-trisfosfaatti- (IP3) tai dopamiinipitoisuuksiin.
Aikaisemmista havainnoista poiketen todettiin, että malliyhdisteet laskivat aivojuovion
solunulkoisen ACh:n määrää. Lasku ei kuitenkaan korreloinut aivojen PREP-aktiivisuuden
kanssa, joten on todennäköistä, että havaittu vaikutus ei liity PREP:n katalyyttisen
aktiivisuuden estoon. ACh-vaikutuksen mahdollista mekanismia selvitettiin seulomalla,
onko aineilla muita sitoutumispaikkoja kuin PREP. Näissä in vitro-kokeissa aineiden
todettiin olevan erittäin selektiivisiä PREP:n estäjiä, joten ACh-vaikutuksen aiheuttama
mekanismi jäi siis epäselväksi.
KYP-2047:n osoitettiin olevan käyttökelpoinen farmakologinen työkalu, jolla voidaan tutkia
keskushermoston PREP:n merkitystä lääkevaikutuksen kohteena. Lisäksi vahvistettin
aiempia havaintoja siitä, että PREP-estäjillä on muistia ja oppimista parantavaa vaikutusta.
Tämän vaikutuksen mekanismi jäi edelleen epäselväksi, mutta tulosten perusteella se ei
todennäköisesti liity kolinergiseen, dopaminergiseen tai IP3-järjestelmään. Lisäksi on
todennäköistä, että PREP ei osallistu proliinia sisältävien peptidien solunulkoiseen
pilkkomiseen, koska PREP on solunsisäinen entsyymi.
Luokitus: WL 104, WL 200, QV 38, QU 136, QU 143
Yleinen suomalainen asiasanasto: keskushermosto; aivot; aivotutkimus; neurokemia; entsyymit; inhibiittorit;
farmakokinetiikka; farmakodynamiikka; neuropeptidit; välittäjäaineet; kognitio; oppiminen; muisti; rotat
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1 Introduction
The activity and lifespan of proteins or peptides in living organisms are highly
dependent on their processing by proteases, i.e. proteolytic enzymes. These enzymes
perform a number of tasks that are vital to the organism, including the regulation of
peptide functions, their post-translational modifications, and digestion into smaller
fragments that can be either inactive or active.
Most peptidases are unable to cleave peptide bonds formed by proline residues because
of the unique cyclic structure of this amino acid. Proline residues are present in many
biologically active peptides, and thus, proline can be considered to protect these peptides
from degradation. There are, however, specific proteases that recognize the cyclic proline
and are able to degrade proline containing bioactive peptides, which makes these proteases
highly interesting drug targets.
One such proline specific protease is prolyl oligopeptidase (PREP; EC 3.4.21.26, also
known  as  prolyl  endopeptidase,  POP,  PE,  PO  or  PEP).  It  was  first  discovered  as  an
oxytocin-cleaving enzyme in uterus in the 1970’s (Walter et al., 1971; Cunningham and
O'Connor, 1997b). It is an 80 kDa cytosolic enzyme of ancient origin belonging to the PREP
family of serine proteases (Venäläinen et al., 2004). Despite the fact that it is an abundant
peptidase in the brain and periphery, the physiological function of PREP is still largely
unknown. It has a rather unique substrate specificity towards proline-containing peptides,
including a variety of bioactive peptides, for example substance P (SP), arginine-
vasopressin  (AVP),  neurotensin  (NT)  and  bradykinin  (see  Cunningham  and  O'Connor,
1997b). Indeed, PREP is able to cleave several naturally occurring proline containing small
peptides in in vitro peptidase assays.
Several of these PREP substrates have been associated with regulation of learning and
memory (see Huston and Hasenohrl, 1995; Cunningham and O'Connor, 1997b; de Wied,
1997), and the highest PREP activities in human brain have been found from those brain
areas closely associated with learning and memory. Therefore, already in the late 1970’s, it
was hypothesized that by inhibiting the catalytic activity of PREP with specific inhibitors,
the brain levels of these promnesic neuropeptides could be elevated.
This neuropeptide hypothesis triggered the search for specific PREP inhibitors.
Subsequently,  hundreds  of  PREP  inhibitors  have  been  synthesized  by  academic  and
industrial research groups with the principal aim to generate antiamnesic drugs. At least
three  of  them  have  even  entered  clinical  trials  as  potential  cognition  enhancers,  but  have
not proceeded to phase III trials for unknown reasons. A compound called S-17092 was
developed by a French pharmaceutical company, Servier, in the 1990’s. S-17092 was tested
in a number of preclinical studies and in clinical phase I and II trials as a potential drug for
Alzheimer’s disease. Despite generally positive results, it never proceeded to phase III
efficacy studies with large patient groups. Another PREP inhibitor, JTP-4819, was generated
for senile dementia by Japan Tobacco Inc. already at mid 1990’s. It was in phase II clinical
trials when the company decided to discontinue the development for unknown reasons in
2001. A Finnish pharmaceutical company Orion Pharma patented two series of PREP
inhibitors with a principal aim to generate drugs for neurogenerative diseases. However,
none of  these  compounds have entered clinical  trials  to  date.  The apparent  failures  in  the
clinical studies indicate that there is a need for more detailed research on the physiological
role  of  PREP,  and  the  pharmacodynamic  (PD)  and  pharmacokinetic  (PK)  properties  of
current PREP inhibitors before they can progress in the drug development process.
Nevertheless, the few clinical trials have shown that certain PREP inhibitors can be
administered to humans without concerns of safety.
2In the last few decades, basic research has provided a number of scenarios for the
physiological relevance of PREP, but these theories have been difficult to prove. Early
reports associated altered plasma/serum PREP activity with several pathological
conditions, such as psychiatric disorders (Maes et al. 1994; Maes et al. 1995). More recently,
the enzyme has been linked with -synuclein aggregation (Brandt et al., 2008), regulation of
synaptic plasticity (Di Daniel et al., 2009; Szeltner et al., 2010), and neural growth-cone
development (Di Daniel et al., 2009). It has also been postulated that PREP is a modulator of
the inflammatory response (Gaggar et al., 2008) and that it participates in angiogenesis
(Myöhänen et al., 2011). Furthermore, novel functions have been proposed for PREP in
intracellular trafficking, sorting and protein secretion (Schulz et al., 2005). PREP has been
also linked to the regulation of the phosphoinositide pathway (Williams et al., 1999).
Interestingly, some of these functions seem to be unrelated to the catalytic activity of the
enzyme. It is not surprising that these novel findings have significantly increased interest in
PREP as a drug target.
Currently, several research groups are attempting to unravel the physiological role of
PREP and the role of oligopeptidase inhibitors in brain function and dysfunction. The
following review of the literature aims to summarize the recent findings about the role of
PREP in health and disease. The first part of the review concentrates on the proposed role
of  PREP  in  the  regulation  of  normal  cellular  functions,  and  the  second  part  discusses  the
association of PREP with several pathological conditions. In addition, the potential of PREP
inhibitors as possible treatments for some of these illnesses is discussed where applicable.
The experimental section of this thesis concentrates on the characterization of the PD and
PK properties of two model PREP inhibitors in rats, and evaluates the potential of PREP as
a central nervous system (CNS) drug target.
32 Review of the literature
2.1 PROLYL OLIGOPEPTIDASE IN THE REGULATION OF CELLULAR
FUNCTIONS
2.1.1 Overview of prolyl oligopeptidase
Prolyl oligopeptidase (PREP; EC 3.4.21.26) is found nearly in all organisms; it is present
from bacterial and archeal species to humans (see Cunningham and O'Connor, 1997b).
PREP belongs to the prolyl oligopeptidase family of serine proteases (clan SC, family S9).
Close relatives of PREP are dipeptidyl peptidase IV (DPPIV; EC 3.4.14.5), oligopeptidase B
(EC 3.4.21.83) and acylaminoacyl peptidase (EC 3.4.19.1) (Venäläinen et al., 2004).
In mammals, PREP is a cylinder shaped 80 kDa soluble protein of 710 amino acids
consisting of two domains. The -hydroxylase domain contains the catalytic residues
(Fülop et al., 1998). The central sequence (residues 73-427) is a 7-bladed -propeller domain
radially arranged around the central tunnel embedded within the cylinder, where the active
site is located.
PREP cleaves peptides at the carboxyl side of an internal proline (-Pro-Xaa-; where Xaa is
not Pro). PREP also cleaves Ala-X bond but at a much lower reaction rate (Polgar, 1992).
Furthermore, PREP has been shown to cleave an apoptosis rescue peptide, humanin, at the
carboxyl side of a cysteine (Bär et al., 2006).
The size limitation of its substrates is the main difference between PREP and most of the
other serine proteases. Eukaryotic PREP is able to digest peptides up to approximately 30
amino acids, but does not cleave larger, more structured proteins. The substrate induces an
opening at the interface of the -hydroxylase and -propeller domains while entering
into the active site, and the relatively small size of the interface only permits access to small
peptides (Fülop et al., 1998). Furthermore, concerted movements of the propeller and the
peptidase domains are required for the substrate binding and the enzyme action (Szeltner
et al., 2004).
Mammalian PREP is encoded by the Prep gene that contains 15 exons (for details, see I).
Earlier,  PREP  was  suspected  to  be  a  housekeeping  enzyme,  since  mouse Prep gene
promoter was characterized by the absence of regulatory elements (Kimura et al., 1999).
The regulatory mechanism of the Prep gene expression is still poorly understood, but recent
reports indicate that the gene is highly regulated across tissues, indicating that PREP is not
a cytoplasmic housekeeping enzyme (Moreno-Baylach et al., 2008; Matsubara et al., 2010).
In addition to the genetic factors, the activity of PREP may be regulated by at least one
endogenous PREP inhibitor (Yoshimoto et al., 1982; Salers, 1994; Tenorio-Laranga et al.,
2010). This inhibitor is poorly characterized, but it suspected to be a cytosolic competitive
inhibitor with a molecular weight of 6.5 kDa. It has been proposed to be a regulator of
PREP enzyme activity in cells, tissues and fluids (see Garcia-Horsman et al., 2007a), but its
physiological role is unknown.
In  peripheral  mammal  tissues,  PREP  protein  is  widely  distributed  in  many  organs,
including placenta (Goossens et al., 1996; Agirregoitia et al., 2005; Myöhänen et al., 2008b;
Matsubara et al., 2011). Generally, the highest peripheral PREP activities have been found
in  the  kidney,  liver  and  lungs.  PREP  activities  in  peripheral  tissues  are  lower  than  those
found in the brain, but higher peripheral activities have been reported in some tissues in
mice (Myöhänen et al., 2008b).
PREP activity has also been detected from human body fluids, although the activities are
low compared to the tissue levels (Goossens et al., 1996). However, this raises the question
4of how PREP has reached extracellular fluids, since the protein is intracellular. Therefore,
the existence of extracellular PREP activity has been subjected to considerable criticism (see
chapter 2.2.1). The physiological role of peripherally located PREP is poorly understood,
but recent findings indicate that peripheral PREP may be involved in the inflammation
process (in lungs) and angiogenesis (Cavasin et al., 2004; Gaggar et al., 2008; Myöhänen et
al., 2011).
PREP  is  found  in  all  regions  of  the  brain  except  for  corpus  callosum.  However,  the
distribution is not homogenous throughout the brain, and activity is associated with
neuronal cells rather than glial cells, suggesting that PREP is involved in neuronal functions
(see I).  In  the  rat,  the  most  enriched  brain  areas  for  PREP  immunoreactivity  are  the
cerebellum, substantia nigra, cerebral cortex and hippocampus (Myöhänen et al., 2007). In
humans, the highest brain PREP activities are found in cerebral cortical areas, hippocampus
and nigrostriatal  pathway,  which could point  to  a  role  for  PREP in  learning and memory
and motor functions (Irazusta et al., 2002; Myöhänen et al., 2007).
PREP is mainly considered as a soluble cytosolic enzyme, although a membrane bound
form (mPREP) has also been characterized (O'Leary and O'Connor, 1995; Tenorio-Laranga
et al., 2008). It has been postulated that mPREP is actually a variant of PREP that has
undergone post-translational modifications, such as addition of a hydrophobic membrane
anchor, necessary for PREP to be associated with membranes (Tenorio-Laranga et al., 2008).
mPREP is significantly less active than cytosolic PREP, and the activity is mainly found in
synaptosomes and endoplasmic reticulum. The role of mPREP remains unknown, although
it has been speculated that it would actually be the enzyme that is responsible for the
extracellular degradation of PREP substrates if it could be extended into the extracellular
space. However, the localization and polarization of mPREP in the membrane is unknown,
and there is no actual evidence that mPREP reaches the synaptic cleft.
Subcellularly, PREP is primarily detected in the perinuclear space tightly associated with
the microtubulin cytoskeleton (Schulz et al., 2005; Myöhänen et al., 2008b), in growth cones
(Di Daniel et al., 2009; Szeltner et al., 2010) and in cell organelle membranes known to be
involved in protein synthesis (Myöhänen et al., 2008b). This subcellular localization could
reflect regulatory functions for PREP in protein secretion, trafficking and processing
(Schulz et al., 2005; Morawski et al., 2011).
2.1.2 General aspects of intracellular peptide processing and signalling
Since PREP has been shown to be present mostly free in the cytosol (Dresdner et al.,
1982; Schulz et al., 2005; Myöhänen et al., 2008a), it would be logical to think that the
physiological functions of PREP could be related to intracellular events. There is increasing
evidence pointing to a role of PREP in the regulation of normal cellular functions such as
axonal transport, protein secretion and intracellular peptide processing.
Intracellular protein degradation is essential for eukaryote cell homeostasis. The
degradation process yields peptides which can then be further degraded into amino acids
and used in synthesizing new proteins (see Goldberg, 2003). PREP may be involved in this
intracellular peptide cycling process through multiple pathways (Figure 1). Free peptides in
the intracellular compartment regulate important cellular functions, such as gene
expression, metabolism, cell signalling and protein targeting (see Joliot and Prochiantz,
2004). Thus, PREP may have importance as a regulator of these functions.
The cell  membrane consists of a lipid bilayer into which proteins and glycoproteins are
attached. The hydrophobic nature of the lipid bilayer makes it impossible for hydrophilic
compounds (such as proteins) to cross the membrane without the assistance of specific
transport mechanisms. Therefore, hydrophilic cargoes are normally carried through the
membrane by transmembrane shuttle proteins. For larger proteins, internalization occurs
by endocytosis, resulting in the uptake of proteins into endocytic vesicles. In addition, an
expanding family of cell-permeable peptides with the ability to reach the cytoplasmic
5compartment after internalization has been described (pathway 2 in Figure 1) (see Joliot
and Prochiantz, 2004). Once translocated into the cytosol, these peptides are freely available
for degradation by cytosolic peptidases such as PREP. Furthermore, free intracellular
peptides may be derived from peptides degraded extracellularly and then actively
transported into the cytosol (pathway 3 in Figure 1).
A large fraction of the newly synthesized proteins is rapidly degraded, within even
minutes of synthesis (Schubert et al., 2000). The degradation takes place mainly in
proteasomes, which are large intracellular protein complexes. The proteasome pathway
(pathway 4 in Figure 1) is thought to be especially important in destructing proteins that
are misfolded or otherwise damaged (see Goldberg, 2003). For example, the proteasome has
been shown to be a key player in the degradation of -synuclein, a major component of the
Lewy bodies forming cytotoxic insoluble fibrils in the brain of Parkinson’s disease patients
(Bennett et al., 1999; Conway et al., 2000; Conway et al., 2001; Gosavi et al., 2002). Inhibition
of the proteasome leads to accumulation of toxic -synuclein aggregates. The peptides
generated by the proteasome in the cytoplasm may serve as substrates for PREP, although
this has not yet been experimentally demonstrated. Furthermore, peptides released by
proteasomes may exert a variety of biological effects, including activation or inactivation of
intracellular peptidases (pathway 5 in Figure 1).
Subcellularly, PREP is located in the perinuclear space tightly associated with the
microtubulin cytoskeleton (Schulz et al., 2005; Myöhänen et al., 2008b), which has
important functions in intracellular protein transport. Interestingly, an overall increase in
protein/peptide release was observed after a human glioma U-343 cell line was treated with
a  PREP  inhibitor  for  24  h,  suggesting  intracellular  functions  for  PREP e.g. in protein
secretion (Schulz et al., 2005).
6Figure 1. Some examples  of  general  pathways  of  intracellular  peptide  formation  and  degradation.  PREP
may be involved in intracellular peptide processing through pathways 2-5. 1) Conventional pathway (black
arrows): following the synthesis and release extracellularly acting peptides bind to cell surface receptors
which mediate their biological effects. The peptide-receptor complexes are then internalized and
transported by vesicles to the endosome where the complexes are dissociated. Peptides are then degraded
in the lysosomes and the free amino acids are excreted into the cytosol. 2) Extracellular peptides can enter
the  cell  via  transmembrane  shuttle  proteins  (blue  arrows).  In  the  cytosol,  they  may  be  degraded  into
amino acids e.g. by PREP and other peptidases (Peps) and join the cytosolic peptide pool. 3) Extracellular
peptides may be degraded extracellularly (e.g. by angiotensin-converting enzyme; ACE) or on the cell
surface  (e.g.  possibly  by  membrane-bound  PREP)  (yellow  arrows).  The  resulting  peptides  are  then
transported into the cytosol, where they may activate or inhibit peptidases such as PREP. 4) Proteasome
pathway (red arrows): Intracellularly acting peptides are derived from intracellular proteins tagged with
polyubiquitin (uuuu). Ubiquitination targets proteins for cleavage by cytoplasmic proteasomes, and the
resulting peptides can then serve as substrates for cytosolic peptidases such as PREP. 5) Intracellular
peptides  released  by  proteasomes  (green  arrow)  may  exert  a  variety  of  effects,  including  activation  or
inactivation of intracellular peptidases (e.g. PREP). Modified from Ferro et al. (2004).
72.1.3 Novel PREP substrates and products
The in vivo effects of PREP inhibitors on brain peptide levels have been characterized
with two potent PREP inhibitors, JTP-4819 and S-17092, and changes in PREP substrate
levels following PREP inhibition have been detected (Table 1; for details, see I). However,
these changes have rarely been dose-dependent, and negative results have also been
reported. It is notable that in particular chronic treatments have been ineffective, suggesting
that other peptidases may compensate for PREP when it is inactivated. In summary,
neuropeptide elevations after PREP inhibition are not invariably detected.
Table 1. The effect of PREP inhibition on neuropeptide levels in rat brain (for details, see I).
Peptide Compound Species Treatment Brain
area/result
Reference
SP JTP-4819 Young rat Single dose
1-3 mg/kg p.o.
CTX 
HC
Toide et al.,
1996
Aged rat Single dose
3 mg/kg p.o.
CTX 
HC 
Toide et al.,
1995b
Aged rat Repeated
1 mg/kg p.o. × 21 days
CTX 
HC 
Toide et al.,
1995b
Young rat Repeated
0.3-3 mg/kg p.o. × 15 days
CTX 
HC 
Shinoda et al.,
1996
S-17092 Young rat Single dose
1-30 mg/kg p.o.
STR  Morain et al.,
2002
Young rat Repeated
1-30 mg/kg p.o. × 7 days
STR  Morain et al.,
2002
Young rat Single dose
10-30 mg/kg p.o.
CTX 
HT 
Bellemere et
al., 2003
Young rat Repeated
10-30 mg/kg p.o. × 8 days
CTX 
HT 
Bellemere et
al., 2003
TRH JTP-4819 Young rat Single dose
1-3 mg/kg p.o.
CTX 
HC 
Toide et al.,
1996
Young rat Repeated
0.3-3 mg/kg p.o. × 15 days
CTX 
HC 
Shinoda et al.,
1996
S-17092 Young rat Single dose
10-30 mg/kg p.o.
CTX 
AMG 
Bellemere et
al., 2005
Young rat Repeated
10-30 mg/kg p.o. × 8 days
CTX  Bellemere et
al., 2005
AVP JTP-4819 Young rat Single dose
1-3 mg/kg p.o.
CTX 
HC
Toide et al.,
1996
Aged rat Single dose
1 mg/kg p.o.
CTX 
HC 
Toide et al.,
1995b
Aged rat Repeated
1 mg/kg p.o. × 21 days
CTX 
HC 
Toide et al.,
1995b
Young rat Repeated
0.3-3 mg/kg p.o. × 15 days)
CTX 
HC 
Shinoda et al.,
1996
S-17092 Young rat Single dose
10-30 mg/kg p.o.
HC 
CTX 
Bellemere et
al., 2005
Young rat Repeated
10-30 mg/kg p.o. × 8 days
HC 
CTX 
Bellemere et
al., 2005
-MSH S-17092 Young rat Single dose
10-30 mg/kg p.o.
CTX 
HT 
Bellemere et
al., 2003
Young rat Repeated
10-30 mg/kg p.o. × 8 days
CTX 
HT 
Bellemere et
al., 2003
 elevated peptide levels;  no change in peptide levels. Abbreviations: -MSH, melanocyte stimulating hormone;
AMG, amygdala; AVP, arginine-vasopressin; CTX, cortex; HC, hippocampus; HT, hypothalamus; SP, substance P; STR,
striatum; TRH, thryrotropin releasing hormone.
8Traditionally, assessments of brain peptide levels have been carried out by treating
animals with a PREP inhibitor and then analyzing the levels of a potential substrate from
crude tissue preparations using antibody based assays such as ELISA or radioimmunoassay
(RIA). However, antibody based assays have to be targeted against a known substrate and
thus, they can be used to test a hypothesis but they cannot detect unknown substrates.
In recent years, efforts to identify possible enzyme substrates have increasingly relied on
the use of mass spectrometry based peptidomics assays that identify changes in the
peptidome associated with changes in the activity of an enzyme (Che et al., 2005; Pan et al.,
2005; Zhang et al., 2008). By using this approach, it is possible to detect multiple
neuropeptides without any prior knowledge of their identities. To date, potential PREP
substrates and cleavage products have been sought in at least three peptidomics studies
(Brandt et al., 2005; Nolte et al., 2009; Tenorio-Laranga et al., 2009). In these experiments,
most of the identified PREP substrates contained an internal proline, suggesting that they
may be potential PREP substrates in vivo.
The first attempt to use the peptidomics approach to identify new potential PREP
substrates was made by Brandt and co-workers (2005). They sought substrates in porcine
brain by incubating brain peptide extracts with recombinant PREP. The peptidomics
analysis revealed 269 masses disappearing and 261 masses appearing in the peptide extract
after incubation with PREP, indicative of potential PREP substrates and products,
respectively. The most interesting peptides produced by recombinant PREP included
fragments  of  myelin  basic  protein  (a  structural  protein  of  myelin)  and  a  small  part  of  -
synuclein protein. They also detected a fragment of phospholipase C (PLC), a key enzyme
in the  phosphoinositol  cycle,  disappearing from the extract,  suggesting that  it  had been a
PREP substrate. Theoretically, this could provide a novel but yet unidentified route for
PREP to affect inositol-1,4,5-trisphosphate (IP3) turnover.
However, the experimental set-up and the PREP digestion were nonphysiological and
unavoidable unspecific post-mortem proteolysis was not sufficiently prevented in the study
by Brandt et al. (2005). Therefore, Tenorio-Laranga et al. (2009) collected the brain samples
from PREP inhibitor treated rats (ZPP 30 mg/kg i.p. 4 h after treatment) and made also
several improvements to the sample preparation and mass spectrometry conditions and
then approximately 200 significantly altered peptides were identified. The peptides were
classified as PREP substrates if their levels were found to increase under PREP inhibition
and as PREP products if the levels were decreased under the same conditions. The
observed PREP products were fragments of large intracellular enzyme complexes or
proteins  or  precursors  of  secreted  peptides.  This  may  point  to  a  role  for  PREP  in
intracellular processing of peptides. It is notable that none of the PREP products were
derived from peptides identified as PREP substrates (=substrate-product pairs), indicative
of the involvement of other proteases in the degradation processes. They also found modest
evidence for the involvement of PREP in the cleavage of classical PREP substrates, namely
SP, TRH, AVP and -MSH.
The latest attempt to use the peptidomics approach to identify PREP regulated peptides
was carried out by Nolte and co-workers (2009). They treated mice with a PREP inhibitor
(S-17092, 30 mg/kg i.p. 1 or 4 h before the sample collection) and analyzed changes in the
brain and spinal cord peptide levels using a label-free peptidomics platform. They were
able  to  detect  changes  in  the  levels  of  23  distinct  peptides,  including  SP,  in  the  brain  1  h
after the PREP inhibitor treatment. Fifteen peptides were classified as PREP substrates and
8 as products. Surprisingly, there were only few substrate overlaps with the earlier
peptidomics assays, probably because these studies tend to vary extensively in their
experimental conditions (i.e. the animal model, inhibitors, time of inhibition and mass
spectrometry technique).
In contrast to the study of Tenorio-Laranga et al. (2009), Nolte et al. (2009) were able to
identify few substrate-product pairs, indicative that the substrates truly were cleaved by
9PREP in vivo. Among the identified PREP substrates perhaps the most interesting were
thymosin 4 (T4) derived peptides Tmsb4x(8-22) and Tmsb4x(8-25), which are precursors
of a pro-angiogenic peptide N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP; see chapter
2.1.7 for detailed discussion). Furthermore, several PREP regulated peptides were identified
as proline rich peptides with two or more prolines in their amino acid sequence. These
proline-rich domains are typically found in proteins associated with protein-protein
interactions, i.e. a possible role for PREP in the regulation of these interactions.
Although the peptidomics studies have identified a number of interesting novel
substrate candidates for PREP, it should be kept in mind that peptidomics methodology is
still relatively new and the validation of the reported results will continue in the future. For
example, it is not known whether the observed changes in the peptidome are a result of
PREP catalytic activity or alterations in gene expression.
Humanin, an interesting novel PREP substrate, was found by Bär and co-workers (2006).
Humanin  is  a  cellular  rescue  factor  and  protects  neurons  from  apoptotic  cell  death  by
preventing the translocation of Bax (Bcl2-associated X protein, an apoptosis-inducing
factor) from cytosol to mitochondria (Guo et al., 2003). PREP was able to cleave humanin in
a cell extract of a human glial cell line U-343, and this could be completely prevented by
addition of a PREP inhibitor CNfmoc (Bär et al., 2006). Interestingly, the PREP catalyzed
hydrolysis  was  found  to  occur  at  the  carboxy  terminal  of  cysteine,  not  proline,  as  would
have  been  expected.  The  authors  concluded  that  PREP  has  limited  post-cysteine  cleaving
specificity, and PREP inhibition might represent a new target for apoptosis prevention.
Earlier, PREP has been associated with neuronal apoptosis in various studies (see I). For
example, a PREP inhibitor, ONO-1603, prevented age-induced apoptosis in cultivated
neurons (Katsube et al., 1999). On the basis of these results, it would be interesting to
confirm the cleavage of humanin by PREP in vivo as well.
Recently, a novel PREP product proline-glycine-proline (PGP) was described (Gaggar et
al.,  2008).  The  role  of  PREP  in  PGP  release  and  the  significance  of  PGP  in  neutrophil
inflammation cascade are discussed in chapter 2.2.5.
2.1.4 Cell proliferation and differentiation
PREP  has  been  suggested  to  have  a  role  in  cell  proliferation  and  differentiation  since
changes in PREP mRNA levels as well as effects of PREP inhibitors on cell regeneration and
tissue differentiation have been reported (see I). It was shown already in early animal
studies that treatment of rats with a synthetic PREP inhibitor, Z-Gly-Pro-CHN2, resulted in
the suppression of liver regeneration, suggesting that PREP plays a role in the growth and
differentiation of liver cells (Yamakawa et al., 1994). Moreover, studies with the flesh fly
Sarcophaga peregrina revealed that PREP is involved in the differentiation of Sarcophaga
imaginal  discs,  since  a  PREP  inhibitor  ZTTA  inhibited  their  differentiation  from  the
eversion to the elongation stage, and that the Sarcophaga PREP gene was activated at the
eversion stage of differentiation (Ohtsuki et al., 1994; Ohtsuki et al., 1997). Furthermore,
elevated PREP activities have been reported in several neoplastic diseases (Sedo et al., 1991;
Goossens et al., 1996; Larrinaga et al., 2010).
Localization data suggest a role for PREP in the nuclear machinery and cell proliferation.
PREP has been found to be present in the nucleus of peripheral cells (Myöhänen et al.,
2008b), and at an early developmental phase, significant PREP activity has been found in
neuronal nuclei as well (Moreno-Baylach et al., 2008; Moreno-Baylach et al., 2011). The role
of PREP in cell proliferation is also supported by the fact that in peripheral tissues PREP
was partially colocalized with nuclear proliferation marker Ki-67 (Myöhänen et al., 2008b).
Recently, the subcellular distribution of PREP in human neuroblastoma cells under
proliferating conditions and under differentiation induced by retinoic acid has been studied
(Moreno-Baylach et al., 2011). After the induction of cell differentiation, PREP activity was
reduced in the nucleus but elevated in the cytoplasm and treatment with PREP inhibitors
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could retard the onset of the differentiation. Moreover, in a primary culture of rat cerebellar
neurons, cytoplasmic PREP activity was found to increase by 10-fold during the neuronal
differentiation, and the peak expression coincided with the moment of complete
differentiation into granular neurons (Moreno-Baylach et al., 2008).
The  expression  of  PREP  mRNA  in  the  rat  brain  and  spinal  cord  from  embryo  to  adult
stages was recently investigated (Agirregoitia et al., 2010). PREP mRNA levels were found
to be more abundant during the perinatal stages, coinciding with a period of neuronal
migration and differentiation. From that time point on, PREP mRNA expression declined,
reaching its nadir levels at adulthood. Based on this data, it was suggested that PREP
mediates specific functions related to neurodevelopment.
In a recent study, a PREP inhibitor SUAM-14746 was shown to suppress the growth of
human neuroblastoma cells in a dose dependent manner without causing cell death
(Sakaguchi et al., 2011). The growth inhibition was associated with pronounced G0/G1 arrest
and a transient inhibition of the S and G2/M phase progression, indicating a role for PREP in
cell cycle regulation.
The localization of PREP in mouse placenta has been reported to change during
development, suggesting that PREP plays a role in the differentiation of some placental
cells or in the establishment of fetal-maternal connection (Matsubara et al., 2011). PREP was
also found to be located in the nucleus of early developing mouse placenta, i.e. involvement
in the regulation of cell proliferation and differentiation.
As  a  summary,  the  current  evidence  suggests  that  PREP  plays  a  role  in  the  cell
proliferation and differentiation. However, no specific mechanisms for this action have
been described. For example, it is not known whether these actions are dependent on the
catalytic activity of PREP. Nevertheless, the recent observation that a PREP inhibitor can
suppress the growth of malignant tumor cells (Sakaguchi et al., 2011) opens an interesting
field for future PREP studies.
2.1.5 Regulation of inositol cycle
Stimulation of a large variety of neurotransmitter receptor subtypes (e.g. muscarinic M1,
M3 and M5, noradrenergic 1 and serotonergic 5-HT2) induces the hydrolysis of membrane
phospholipids. The binding of an agonist to these kinds of receptors activates G proteins
which stimulate PLC. PLC hydrolyses phosphatidylinositol bisphosphate (PIP2) into two
second messengers, diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (IP3). IP3
stimulates the mobilization of intracellular calcium (Ca2+) from endoplasmic reticulum and
DAG activates protein kinase C (PKC) (Figure 2). Intracellular Ca2+ has many vital functions
e.g. in signal transduction and in muscle cell contraction.
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Figure 2. The  role  of  PREP  in  the  inositol  cycle. Upon cell stimulation phospholipase C (PLC) converts
phosphatidylinositol bisphosphate (PIP2) into inositol-1,4,5-trisphosphate (IP3), which triggers calcium
(Ca2+) release from intracellular  storages.  Another route to produce IP3 is  to degrade high order inositol
phosphates (IP6, IP5 and IP4), which is catalyzed by multiple inositol polyphosphate polyphosphatase
(MIPP). PREP regulates MIPP activity, and reduced PREP activity (by inhibition or mutation) leads to
enhanced degradation of high order phosphates and increased IP3 levels. IP3 is further degraded by inositol
polyphosphate 1-phosphatase (IPP) and inositol monophosphatase (IMPase) to inositol. Inositol is
incorporated into PIP2 by PI synthase, PI4 kinase and PI5 kinase. Lithium inhibits IPP and IMPase, which in
turn causes inositol depletion and slows down the inositol cycle. (The diacylglycerol (DAG) hydrolyzation
route of PIP2 was  excluded  from  the  illustration  for  clarity  reasons).  (Williams  and  Harwood,  2000;
Harwood, 2011).
The  link  between  PREP  and  IP3 was  first  established  when  it  was  discovered  that  the
mutated social amoeba Dictyostelium discoideum missing the Prep gene (DpoA mutant) was
resistant to the well-documented inositol and IP3 depleting effect of lithium (Williams et al.,
1999). Lithium inhibits inositol monophosphatase (IMPase) and inositol polyphosphate 1-
phosphatase (IPP), which are key enzymes in the production of inositol. The concentration
of  the  second  messenger  IP3 is dependent on the amount of available inositol, which is
depleted during lithium treatment, resulting in reduced IP3 levels (Berridge et al., 1989).
Reduced PREP activity  can counteract  this  and increase  the  amount  of  IP3 during lithium
treatment (Williams et al., 1999). The same effect has been observed in wild-type cells
treated  with  a  PREP  inhibitor,  suggesting  that  reduced  PREP  activity  can  enhance  the
turnover  of  phosphoinositides  and  increase  the  cellular  concentration  of  IP3, probably by
regulating the multiple inositol polyphosphate polyphosphatase (MIPP), the enzyme which
produces IP3 by dephosphorylating IP6, IP5 and IP4 (Williams et al., 1999; Schulz et al., 2002).
The IP3 elevating effect of PREP inhibition may not arise from direct elevation of IP3
production, but is due to changes in genes encoding inositol synthesis and recycling (King
et al., 2010). These include IMPase (impA1),  inositol  synthase  (ino1), IPP and IP3
5’phosphatase genes. MIPP and PREP are key components in the gene regulatory network
that controls inositol synthetic genes, however, the mechanism leading to gene expression
changes remains unknown and requires clarification.
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A number of studies have linked PREP and inositolphosphate signalling in mammalian
cells  as  well.  There  is  an  inverse  correlation  between  the  IP3 concentration  and  PREP
expression in mammalian neuronal cells (Schulz et al., 2002). In primary neurons, lithium-
mediated growth cone spreading is reversed by PREP inhibition (Williams et al., 2002) (see
also chapter 2.1.6.) Furthermore, PREP and IP3 type 1 receptor (IP3R1) are highly colocalized
in  distinct  areas  of  rat  brain,  hinting  at  a  regulatory  relationship  between  PREP  and  IP3
(Myöhänen et al., 2008c; Myöhänen et al., 2009).
A simple scenario to explain the proposal that PREP is involved in the inositol cycle
would be that PREP regulates the activity of crucial intracellular peptides involved in the
phosphorylation/dephosphorylation cascades of the inositol cycle. Despite several attempts
using the peptidomics approach, however, no IP3 regulating peptides have been found.
Furthermore, the connection between IP3 and PREP has never been observed in any of the
in vivo models.
2.1.6 Regulation of neuronal growth
The growth cone is a specialized area at the tip of the extending axon that is responsible
for sensing the local environment and moving towards the neuron’s synaptic target (see
Kalil and Dent, 2005). The growth cones are hand-shaped with several long finger-like
filopodia reaching out to touch or sense the environment. Growth cones are key elements in
axon guidance, directing the initial wiring of the nervous system during development and
they are also important in axonal regeneration following an injury.
There are recent findings for a role for PREP in the regulation of neuronal growth cone
dynamics. Three mood stabilizing drugs, lithium, carbamazepine and valproate, cause
similar changes in the growth cone dynamics of rat sensory neurons in vitro (Williams et al.,
2002). These changes, i.e. the decrease in number of collapsed growth cones and the
increase in the growth cone area, can be reversed by addition of myo-inositol indicating
that these drugs act via inhibition of the inositol cycle. Interestingly, PREP inhibitors can
reverse the effects of the three mood stabilizers on the growth cone dynamics thus
mimicking the action of inositol.
Di Daniel and co-workers (2009) studied the growth cone response of mood stabilizing
drugs in PREP null-mutant (PREP-/-) mouse neurons and found out that untreated PREP-/-
neurons  differed  from  wild-type  PREP+/+ neurons  in  terms  of  growth  cone  area  and
collapse. However, the PREP-/- phenotype could be completely reversed with the
transduction of either native or a catalytically inactive PREP. This is a clear indication that
PREP regulates the growth cone dynamics via cytosolic protein-protein interactions rather
than via its peptidase activity.
Potential intracellular PREP protein binding partners that could mediate the growth cone
response were sought using yeast-two-hybrid assays (Di Daniel et al., 2009). For example,
growth-associated protein 43 (GAP-43) was identified as a possible PREP interactor in
yeast. GAP-43 has been shown to be involved in several cellular functions, such as growth
cone formation and axon guidance, cellular signalling, synaptic plasticity,
neurodegeneration and apoptosis (see Aigner and Caroni, 1993; Benowitz and Routtenberg,
1997; Denny, 2006). It is a particularly interesting PREP binding partner, since it has been
shown to be predominantly expressed in the brain areas involved in cognitive processes
(Neve et al., 1988; Benowitz et al., 1989). Furthermore, PREP has been shown to partially co-
localize and bind to GAP-43 in mammalian cells (Di Daniel et al., 2009; Szeltner et al., 2010).
It can be hypothesized that a protein-protein interaction between PREP and GAP-43
would affect many processes in which GAP-43 is involved, and thus could also explain the
altered  growth  cone  dynamics  of  PREP-/- mouse neurons. However, Szeltner and co-
workers (2010) could not find any strong physical interaction between these proteins.
Instead of a direct physical interaction, PREP could affect the functions of GAP-43 via an
indirect pathway. For example, PREP has been associated with tubulin, the main structural
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component of the microtubulin cytoskeleton (Schulz et al., 2005). Microtubules play a key
role in intracellular trafficking and axonal transport. Since GAP-43 is axonally transported
into the growth cones, PREP could interfere with this transportation system and thus affect
the GAP-43 mediated cellular functions.
If  the  effects  of  PREP  on  the  growth  cone  dynamics  are  mediated  through  protein-
protein interactions and not through the catalytic activity of the enzyme, this raises the
question  how  PREP  inhibitors  can  modulate  these  non-catalytic  actions.  This  could  be
explained by the fact that the access of substrates to the catalytic site of PREP involves the
movement of a flexible loop, which evokes conformational changes in the tertiary structure
of the enzyme (Fuxreiter et al., 2005). Since most PREP inhibitors are substrate-like
compounds,  it  is  likely  that  the  binding  of  the  inhibitor  to  the  enzyme  causes  similar
conformational changes, which in turn could perturb the protein-protein interactions.
2.1.7 Regulation of angiogenesis
A recent intriguing finding in PREP biology relates to its association with T4, the most
abundant -thymosin in mammals (see Hannappel, 2010). T4 is a 43 amino acid peptide
which has been proposed to possess cardioprotective properties. For example, intracardiac
or intraperitoneal T4 administration in a mouse model of myocardial infarction improved
cardiac function and enhanced myocyte survival (Bock-Marquette et al., 2004).
Furthermore,  exogenously  administered  T4  affects  inflammatory  events  and  wound
healing (Young et al., 1999; Bock-Marquette et al., 2004; Sosne et al., 2007). T4 has also
been linked to angiogenesis (i.e. the formation of new blood vessels) in a number of in vitro
and in vivo studies (Grant et al., 1995; Malinda et al., 1997; Koutrafouri et al., 2001;
Myöhänen et al., 2011). Indirect evidence of the involvement of T4 in angiogenesis
emerges  from the  observation that  it  is  overexpressed in  a  number  of  human tumors  and
the overexpression correlates to malignant progression (Conlon et al., 1988; Hall, 1991).
Ac-SDKP is the N-terminal amino acid sequence (T4 2-5) of T4 (see Hannappel, 2010).
Ac-SDKP is present in the blood, and it has been shown to decrease cardial fibrosis, prevent
collagen synthesis in vitro, and have anti-inflammatory properties in rats (Peng et al., 2001;
Rhaleb et al., 2001a; Rhaleb et al., 2001b; Yang et al., 2004; Sharma et al., 2008). Ac-SDKP is
hydrolyzed in plasma by ACE, and it has been suggested that some of the cardioprotective
effects of ACE inhibitors may be mediated through elevated plasma levels of Ac-SDKP
(Junot et al., 2001; Wang et al., 2004). It has been shown in vitro that  PREP  is  the  main
enzyme responsible for the cleavage of Ac-SDKP from T4 (Cavasin et al., 2004). It was
shown using rat kidney cortex homogenates that Ac-SDKP was generated from exogenous
4, and this generation was significantly reduced by addition of several PREP inhibitors.
Furthermore, in vivo studies in rats have demonstrated that long term administration of the
PREP inhibitor, S-17092, significantly decreased the plasma levels of Ac-SDKP, and
prevented the Ac-SDKP increase induced by an ACE inhibitor, captopril, in the plasma,
urine, heart and kidney (Cavasin et al., 2004).
Since PREP is not known to be able to cleave peptides larger than 30 amino acids, it is
unlikely that the 43 amino acid long T4 would be a PREP substrate. Therefore, a preceding
cleavage step would be necessary to produce suitable PREP substrates from T4. Indeed, it
has been demonstrated that PREP does not cleave whole T4, but is a second step enzyme
in the release of Ac-SDKP from T4 (Myöhänen et al., 2011). Furthermore, a PREP inhibitor,
KYP-2047, can block the release of Ac-SDKP from T4 in rat kidney homogenate. The first
step in T4 cleavage is attributable to unidentified protease(s), and interestingly, PREP was
shown to inhibit these first step proteases, thus autoregulating the release of Ac-SDKP. This
effect could be independent on the hydrolytic activity of PREP, or alternatively, PREP could
generate peptide products that inhibit the proteases responsible for the initial cleavage of
whole T4. Since T4 is located intracellularly, the Ac-SDKP release is probably an
intracellular event, which is also appropriate in view of the intracellular location of PREP.
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Ac-SDKP promotes angiogenesis both in vitro and in vivo (Liu et al., 2003; Wang et al.,
2004). Pathological angiogenesis is a hallmark of cancer as well as various inflammatory
and ischemic diseases (Carmeliet and Jain, 2000). The plasma and bone marrow Ac-SDKP
levels have been shown to be elevated in patients with leukemia, and overexpression of Ac-
SDKP has been associated with cancer (Liu et al., 2010). Since PREP may play a role in the
release of Ac-SDKP, it has become interesting to study the association of PREP with
angiogenesis (Myöhänen et al., 2011). PREP was found to increase and the PREP inhibitor,
KYP-2047, decreased angiogenesis in vitro and in vivo. The observed decrease in
angiogenesis opens new possibilities for future research examining PREP inhibitors in
tumor models.
4 is also expressed in the brain. Nolte and co-workers (2009) studied the peptidomics
of PREP in mice brain, and found evidence for PREP involvement in the cleavage of T4 in
the CNS as well. Two T4 derived Ac-SDKP precursors, Tmsb4x(8-22) and Tmsb4x(8-25),
were found to be elevated in mouse brain after a single dose treatment with S-17092,
indicating that T4 cleavage is dependent on PREP activity in the brain as well. The role of
Ac-SDKP in the CNS is unknown, but this study indicates that the T4-Ac-SDKP pathway
could represent important new functions for PREP in the CNS.
2.2 ROLE OF PREP AND PREP INHIBITORS IN DISEASE PROCESSES
2.2.1 Problems associated with plasma PREP activity measurements
Changes in human plasma/serum PREP activities have been described in several
pathological conditions (Table 2). However, no specific mechanisms have been established
to  account  for  these  altered  activities.  Furthermore,  the  relevance  of  the  plasma  PREP
activity studies was questioned when it was discovered that the reported plasma enzyme
activity consisted of two separate enzymes, namely PREP and Z-L-prolyl-L-prolinal
insensitive Z-Gly-Pro-7-amino-4-methylcoumarin hydrolyzing peptidase (ZIP)
(Cunningham and O'Connor, 1997a; Birney and O'Connor, 2001). Later ZIP was
characterized and identified as seprase or fibroblast activation protein  (FAP) (Collins et
al., 2004). When Z-Gly-Pro-AMC is used as the substrate in activity assays, ZIP/FAP
accounts for about 60% of the plasma activity previously attributed to PREP, but its activity
in other tissues than blood has not been described. Therefore, the observed alterations in
the plasma PREP activity in different diseases may reflect the enzymatic activity of
ZIP/FAP rather than PREP.
ZIP/FAP and PREP have several common proline-containing substrates, but ZIP/FAP is
completely resistant towards ZPP inhibition (Cunningham and O'Connor, 1997a; Birney
and O'Connor, 2001). Furthermore, in humans, ZIP/FAP activity seems to be restricted to
plasma, whereas blood PREP activity can be detected in the lymphocytes and plasma
(Breen et al., 2004). Since ZIP/FAP has been shown to be a substantial component of plasma
based PREP assays, clinical studies using plasma samples need to be re-examined in order
to eliminate the possible contaminating role of ZIP/FAP. On the other hand, an interesting
question is how PREP and ZIP/FAP activities are even found in plasma, since plasma is the
extracellular component of blood, whereas PREP protein is known to be cytosolic
(Myöhänen et al., 2008a) and FAP a membrane bound glycoprotein (O'Brien and O'Connor,
2008). Furthermore, it is questionable to what extent the plasma enzyme activity reflects the
brain enzyme activity in disease states.
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Table 2. Observed changes in plasma/serum PREP activity in various pathological conditions.
Disease Change in plasma PREP
activity
References
Alcoholism  Maes et al., 1999a
Anorexia and bulimia
nervosa
 Maes et al., 2001
Autistic spectrum disorder
(ASD)

(+ much higher variation in
plasma PREP activity of ASD
patients
Momeni et al., 2005
Bipolar disorder
- Lithium-treated patients
- untreated patients


Breen et al., 2004
Maes et al., 1995
Depression  Maes et al., 1994 & 1995
Mania  Maes et al., 1995
Post-traumatic stress
disorder
 Maes et al., 1999b
Schizophrenia  Maes et al., 1995
Stress induced anxiety  Maes et al., 1998
, increased plasma PREP activity;, decreased plasma PREP activity
2.2.2 PREP in depression
In clinical studies, plasma PREP activity has been found to be significantly lower in
patients with depression in comparison to the activity in healthy individuals (Maes et al.,
1994; Maes et al., 1995) (Table 2). The activity also correlated with the severity of the
symptoms; the individuals with the most severe depression had the lowest plasma PREP
activities. Interestingly, patients treated with antidepressants such as fluoxetine displayed
significantly higher plasma PREP activity than untreated patients (Maes et al., 1995).
However, these data need to be interpreted with caution because of the complexity of
plasma PREP activity measurements, especially in view of the poor relevance of
extracellular PREP (see chapter 2.2.1). Furthermore, although statistically significant, the
observed changes were rather small, typically 10% less than the healthy controls.
There is increasing evidence indicating that various stress-responsive neuropeptide
systems play important pathogenic roles in depressive conditions as well as in other stress-
related disorders (see Brain and Cox, 2006; Alldredge, 2010). Neuropeptides are important
in governing the hypothalamic-pituitary-adrenal (HPA) axis, and perturbations in the HPA
axis are common markers of depression and anxiety.
Since PREP has been closely associated with the metabolism of neuropeptides and
alterations in plasma PREP activities have been described in patients with major
depression,  the  effects  of  two  novel  PREP  inhibitors  in  two  animal  models  of  depression
were recently studied (Krupina et al. 2011). The first of these experimental depression
syndromes was induced in rats by administering the neurotoxin 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) leading to a DA deficient state. In the second model, the
animals were exposed to an irreversible DPPIV protease inhibitor (Met-Prd-N) during the
early postnatal period. Both models lead to depression-like behavioral changes, and
increased PREP activity in various brain areas.  Subchronic (10 days) administration of the
PREP  inhibitors,  Z-Met-Prd-N  (2  mg/kg  i.p.)  and  Z-Ala-Pro-OH  (3  mg/kg  i.p.)  (Ki values
against rat cortical PREP 1.4 nM and 90 μM, respectively), were found to suppress the
depression-like  behavior  in  Porsolt’s  forced  swimming  test  (FST), i.e. antidepressant-like
effects. However, the Ki value of Z-Ala-Pro-OH against PREP is poor, and it is not plausible
that the effect seen in FST would be dependent solely on brain PREP inhibition.
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There is not much other experimental data linking PREP inhibitors to antidepressant
action. A variety of recognized psychopharmacological compounds were tested for their
inhibitory action against PREP in vitro,  but  only  weak  if  any  inhibition  was  observed
(Peltonen  and  Männistö,  2011),  and  it  is  doubtful  if  such  minor  inhibition  would  be
therapeutically important. One unpublished study in rats claimed dose-dependent
antidepressant-like effects for ORM-12139 (1-3 mg/kg s.c.; compound also known as KYP-
2153) in FST (personal communication, Johanna Holappa, Orion Pharma). In an attempt to
elucidate the possible mechanism of the antidepressant action of ORM-12139 (3 mg/kg s.c.),
the activation of the brain derived neurotrophin factor (BDNF) receptor TrkB in rat
prefrontal cortex was measured, but no significant effect on this marker of neuronal
plasticity and antidepressant drug action (Castren and Rantamäki, 2010) was observed
(Jalkanen et al., unpublished data).
PREP has been primarily associated with neuropeptide metabolism, but it is difficult to
explain the few observed antidepressant actions of PREP inhibitors through elevations in
brain neuropeptide levels. In fact, several PREP substrates, such as SP and AVP, have been
shown  to  hyperactivate  the  HPA  axis,  and  thus,  induce  stress  related  behavior  and  they
seem to possess anxiogenic and depressive properties in rodents (Ebner et al., 2004; Dinan
and Scott, 2005; Ebner and Singewald, 2006; Ebner and Singewald, 2007; Ebner et al., 2008).
On the other hand, the PREP substrate, oxytocin, has been suggested to have protective
properties against stress and anxiety (Campbell, 2008). Moreover, it is possible that the
antidepressant actions are mediated by the inhibition of the non-catalytic actions of PREP.
Taken together, the available experimental data does not support a major role for PREP
inhibitors in the treatment of depression or anxiety.
2.2.3 Neurodegenerative diseases
Post mortem brain PREP activity has been reported to be altered in several
neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease,
Huntington’s disease and multiple sclerosis (MS) (Mantle et al., 1996). Earlier, the link
between PREP and neurodegeneration was based on the possible role of PREP in neuronal
apoptosis (see I). Recently, some new mechanisms through which PREP could be involved
in neurodegeneration have been proposed. These mechanisms and the current knowledge
of the role of PREP in the neurodegenerative diseases are discussed below.
Neuroinflammation
There is a substantial amount of evidence pointing to a role for neuroinflammation in the
pathogenesis of neurodegenerative diseases such as AD and Parkinson’s disease (see
Hirsch and Hunot, 2009; Lee et al., 2010; Philips and Robberecht, 2011). There is some data
associating PREP with the inflammatory process (see chapter 2.2.5). Since brain PREP
activity has been reported to be altered in several neurodegenerative diseases (see below), it
is tempting to draw a connection between PREP, neuroinflammation and
neurodegeneration (Penttinen et al., 2011).
Neuroinflammation is distinct from the inflammatory conditions occurring in other
organs. Neuroinflammation is characterized by microglia activation in the primary
inflammatory state. Leukocyte invasion, when it occurs, is a secondary phenomenon as a
consequence of blood-brain barrier disruption (see McGeer and McGeer, 2004). Microglia
activation results in a flooding of surrounding tissue with inflammatory mediators,
oxidizing free radicals, pro-apoptotic factors, matrix-degrading proteases and
chemoattractant  molecules.  In  the  lungs,  PREP  is  believed  to  play  a  role  in  the  release  of
one such chemoattractant, PGP, (Gaggar et al., 2008; O'Reilly et al., 2009), but there are no
reports linking PGP and neuroinflammation. Moreover, PREP has been considered to be
the main enzyme in the release of an anti-inflammatory tetrapeptide Ac-SDKP from T4 in
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the brain (Yang et al., 2004; Sharma et al., 2008; Nolte et al., 2009). In summary,
neuroinflammation seems to be one of the most intriguing targets for future PREP research.
Alzheimer’s disease
AD is the most common neurodegenerative disease and a major cause of dementia in the
elderly, with an estimated prevalence of approximately 4% of individuals over 60 years of
age (see Ballard et al., 2011). The early symptoms are seen as inability to acquire new
memories. As the disease advances, symptoms expand to involve long-term memory loss,
aggression and mood swings, etc., and ultimately AD leads to loss of bodily functions and
death of the subject.
Senile plaques spreading over the cortical brain areas are typical neuropathological
hallmarks of AD (see Ballard et al., 2011). The main protein component of these plaques is
amyloid -peptide (A).  Deposition of A triggers neuronal dysfunction and death in the
brain. This peptide derives from the -amyloid precursor protein (APP). Under normal
conditions, APP is cleaved by -secretase to generate soluble APP which precludes A
generation. The presence of APP has been suggested to enhance neuronal survival,
synaptic plasticity, learning and memory (Han et al., 2005; Zhang et al., 2011).
The -secretase pathway of APP processing can be stimulated by PLC-linked receptor
activation. These receptors include metabotropic glutamate (Lee et al., 1995), muscarinic
ACh (Nitsch et al., 1992) and serotonin 5-HT2a and 5-HT2c receptors (Nitsch et al., 1996). The
activation of PLC results in the generation of two second messengers, DAG and IP3, which
subsequently release calcium from intracellular storages (Figure 2). Interestingly, PREP
inhibition increases intracellular IP3 levels,  which  may  contribute  to  the  stimulation  of
APP production, which would in turn decrease A generation. However, this theory has
not been experimentally tested.
APP can also be cleaved sequentially by -secretase and -secretase to release
extracellular peptide fragments called A1-40/1-42.  These  neurotoxic  fragments  can
oligomerize and at later stages form insoluble aggregates ultimately leading to the
formation of senile plaques (Ballard et al., 2011; Zhang et al., 2011). Since the aggregation of
 in the brain seems to be a primary cause of AD, the inhibition of A generation has
become a topic of much current research. Thus, the levels of several enzyme activities that
may be involved in the generation of A, including PREP, have been measured from post-
mortem AD brains. Both increased and decreased levels of PREP activity have been assayed
in brains of AD patients (Aoyagi et al., 1990; Ichai et al., 1994; Mantle et al., 1996; Terwel et
al., 1998). The decreased levels have been attributed to the oxidative stress induced by
antemortem hypoxia (Garcia-Horsman et al., 2007a; Terwel et al., 1998). Furthermore,
Rossner et al. (2005) found less PREP immunoreactive neurons in brain structures of AD
patients affected by A plaques.
It  is  unlikely  that  the  PREP  hydrolyzing  activity  contributes  to  the  production  of  A.
Purified human PREP does not degrade synthetic A1-40/1-42 in vitro, which is not surprising
given that A1-40/1-42 do not contain internal proline and are too large to be PREP substrates.
The  A precursor  protein  APP  does  have  internal  prolines  in  its  amino  acid  sequence,
but it is a large protein (~700 amino acids) and does not meet the size criterion of a PREP
substrate. Theoretically, PREP could be a second step enzyme in APP cleavage, but here too
the  substrate  size  seems  to  be  a  limiting  factor.  Indeed,  two  PREP  inhibitors,  ZPP  and  S-
17092, had no effect on A1-40/1-42 production in a human cell line (Petit et al., 2000)
supporting the belief that PREP does not participate in APP cleavage. On the other hand,
infusion  of  soluble  A25-35 (a shorter, biologically active fragment of A) into rat
hippocampus or frontal cortex resulted in increased PREP activities in those brain areas
(Arif et al., 2009), but the significance of this change is not clear. Moreover, correlations
between PREP activity in brain regions with A –like immunoreactivity in human and
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senescence accelerated mice have been conflicting (Fukunari et al., 1994; Kato et al., 1997;
Rossner et al., 2005).
Taken together, the data linking PREP activity to the pathological changes in AD are not
consistent, and it seems more likely that the observed changes in brain PREP activity in AD
are associated with neuronal damage rather than A accumulation (Laitinen et al., 2001).
Thus, it is unlikely that one could prevent A generation and achieve a reduction of senile
plaque formation in AD with PREP inhibitors.
Multiple sclerosis
MS is a progressive neurodegenerative disease of the CNS affecting more than two
million people all around the world (see Dutta and Trapp, 2011). The underlying cause of
the disease is still unknown, but the pathological hallmarks of the disease are the presence
of multifocal inflammatory demyelinated plaques distributed over time and space within
the CNS. Other typical pathological findings are the disruption of the blood-brain barrier,
oligodendrocyte loss, reactive gliosis and axonal degeneration (see Dutta and Trapp, 2007;
Trapp and Nave, 2008), the latter probably being the major cause of the progressive
neurological disability. The primary phase of the disease is termed relapsing-remitting MS
(RR-MS), and during this phase patients experience alternating episodes of neuronal
disability and recovery (Ebers et al., 2008). However, within 25 years, 90% of patients
transform into a secondary-progressive disease course with a steady neurological disability.
PREP has been associated with several factors that might be relevant to MS. For instance,
PREP is involved in the regulation of the inflammatory response (Gaggar et al., 2008) and
microglia toxicity (Klegeris et al., 2008). Indeed, a recent report established a direct
connection between PREP and MS; the plasma PREP activities of patients with RR-MS were
significantly reduced (Tenorio-Laranga et al., 2010). Interestingly, the reduction correlated
with the severity of disease symptoms, but not with patient age. Instead, an inverse
correlation between PREP activity and age was observed in healthy controls, and in elderly
controls the levels were comparable to those found in MS patients.
The reduction in the plasma PREP activity of MS patients could partly be explained by
the substantial increase in the levels of an endogenous PREP inhibitor (see chapter 2.1.1).
Another explanation could be that PREP activity is reduced because of the oxidative stress
induced by the disease (Koch et al., 2006; Koch et al., 2007). It does seem that the reduced
plasma PREP activity correlates with the symptoms of the disease. It is worth noting that
the study by Tenorio-Laranga et al. (2010) was more reliable than many others investigating
plasma PREP activity, since ZIP/FAP activity in plasma was separated from PREP activity.
Parkinson’s disease
Parkinson’s disease is a progressive neurodegenerative disorder affecting 1% of
individuals over 60 years old (see Samii et al., 2004). The motor symptoms of the disease
include resting tremor, rigidity, akinesia and bradykinesia, and these occur when
approximately 60-80% loss of DAergic neurons projecting from the substantia nigra pars
compacta to the striatum.
Reduced PREP activity has been reported in brain tissue of Parkinson’s disease patients
(Mantle et al., 1996). Furthermore, the PREP activity in the cerebrospinal fluid (CSF) of
patients with Parkinson’s disease was significantly lower than the PREP activity of control
patients, while activity in plasma did not change significantly (Hagihara and Nagatsu,
1987). However, it is not known whether the CSF PREP activity is a reliable measure of
brain  PREP activity,  since  CSF is  an extracellular  fluid and PREP is  mainly  located in  the
cytosol of neurons. Moreover, the reported plasma activity may have been attributable to
peptidases other than PREP (see chapter 2.2.1).
The neuropathological hallmark of Parkinson’s disease is the progressive degeneration
of melanised DAergic neurons in substantia nigra pars compacta together with intracellular
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inclusions known as Lewy bodies. A major component of the Lewy bodies is a 140 amino
acid protein, -synuclein. This is a protein enriched in the presynaptic terminals of neurons,
but its function in the neuron is largely unknown (Spillantini et al., 1997; Fellner et al.,
2011). -Synuclein is not only found in the brains of Parkinson’s disease patients, but it also
has a role in other neurodegenerative diseases such as dementia with Lewy bodies, the
Lewy body variant of AD, multiple system atrophy, and neurodegeneration with brain iron
accumulation type I (Uversky, 2007).
Under normal conditions, -synuclein is degraded mainly by the high-capacity
intracellular ubiquitin/proteasome pathway (pathway 4 in Figure 1). There are factors
known to decrease the activity and clearance capacity of the proteasome, e.g. age and
oxidative stress (Cuervo et al., 2010). Under certain conditions, -synuclein monomers
interact to form prefibrillar aggregates or protofibrils, which can create cytotoxic insoluble
fibrils (Conway et al., 2000; Conway et al., 2001; Gosavi et al., 2002). These fibrils cannot be
degraded by the proteasome, and they impair the function of this intracellular proteolytic
system. This leads to an accumulation of -synuclein protofibrils (and other proteins that
are degraded by the proteasome) in the cytosol (Bennett et al., 2005) and as a consequence,
-synuclein protofibrils are increased in brains of Parkinson’s disease patients. These fibrils
have been associated with neurotoxicity in -synuclein overexpressing cells and mouse
models (Masliah et al., 2000; Gosavi et al., 2002).
Abnormal accumulation of misfolded -synuclein may lead to mitochondrial changes
which can promote oxidative stress and evoke cell death (Hsu et al., 2000). Furthermore,
three point mutations (A53T, A30P or E46K) in the -synuclein gene are known to be
involved in the pathogenesis of familial form of Parkinson’s disease (Polymeropoulos et al.,
1997; Zarranz et al., 2004).
However, although -synuclein seems to be a major contributor to Parkinson’s disease, it
is still not clear which form of the -synuclein aggregates induce cell death in neurons (Xie
et al., 2010). It has also been postulated that certain fibrillar -synuclein aggregates could
even represent a cytoprotective mechanism (Caughey and Lansbury, 2003; Kaplan et al.,
2003). For example, in neuronal cell lines, overexpression of wild type -synuclein offered
protection against the oxidative stress through some unknown mechanism, but the mutated
(A53T and A30P) forms resulted in increased oxidative stress damage (Lee et al., 2001).
The link between PREP and -synuclein was first established by Brandt and co-workers
(2005) when they were searching for endogenous PREP substrates from a porcine brain
homogenate using mass-spectrometry based peptidomics analysis and recombinant PREP.
Several potential PREP substrates and products were identified; among them a hexapeptide
YQDYEP, which was found to be identical with porcine -synuclein residues 133-138,
suggesting that PREP had been involved in the cleavage of -synuclein downstream to the
primary cleavage site.
In a subsequent study, it was shown that PREP did not cleave intact purified
recombinant -synuclein (Brandt et al., 2008). This is understandable in view of the fact that
PREP cleaves peptides only shorter than 30 amino acids and -synuclein (140 amino acids)
does not meet this criterion. Therefore, it is likely that the putative PREP product YQDYEP
was  not  cleaved  by  PREP  from  full-length  -synuclein  but  from  a  truncated  form.  It  has
been shown that -synuclein is mainly degraded by the intracellular ubiquitin-proteasome
pathway (Bennett et al., 1999), and intracellular peptidases are known to further degrade
the peptides generated by the proteasome. Thus, PREP might play a role in the final stages
of -synuclein cleavage in the brain.
Furthermore, it was shown in vitro that the aggregation rate of -synuclein was
enhanced when the protein was incubated with a clone of wild-type porcine PREP, and this
enhancement depended upon the PREP concentration (Brandt et al., 2008). Moreover, a
mutated variant without PREP activity (S544A) did not accelerate the aggregation rate.
Enhanced aggregation could also be prevented by the addition of PREP inhibitors,
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suggesting that the effect was dependent on the PREP enzymatic activity. Thus, PREP
possibly binds to the monomeric or aggregated -synuclein with its catalytic centre, since
the accelerating effect on aggregation can be reversed by mutation and inhibitors.
A protein-protein interaction between PREP and -synuclein was reported in yeast (Di
Daniel et al., 2009). Recent evidence has suggested that PREP inhibitors can block the
increased -synuclein aggregation induced by oxidative stress in human -synuclein over-
expressing neuroblastoma SH-SY5Y cells (Lambeir, 2011). PREP colocalizes with -
synuclein in SH-SY5Y cells, and this colocalization disappears after incubation with PREP
inhibitors, pointing to an interaction between PREP and -synuclein.
The association between PREP and -synuclein may have interesting clinical
implications in the future. Theoretically, inhibition of brain PREP activity could prevent -
synuclein aggregation and thus, prevent the formation of the cytotoxic protofibrils present
in the Lewy bodies. Therefore, PREP inhibitors could potentially have therapeutical value
in the treatment of neurodegenerative disorders where accelerated -synuclein aggregation
has  been  described.  However,  before  such  a  claim  can  be  made,  thorough  studies  on  the
role of PREP and PREP inhibitors in -synuclein aggregation in vivo will  need  to  be
conducted e.g. using transgenic mouse models exhibiting fibrillar -synuclein inclusions
(Giasson et al., 2002; Lee et al., 2002).
2.2.4 Learning and memory
Originally,  PREP  inhibitors  were  developed  with  the  principal  aim  of  generating  anti-
amnesic drugs (see I). The effects of several PREP inhibitors in various cognitive tasks have
been characterized, and there is some kind of consensus that PREP inhibitors have positive
effects on learning and memory (Table 3). However, the effects in rodents have been
relatively weak, rarely dose-dependent, and have been difficult to replicate. This may
explain the fact that only a few studies investigating the cognitive effects of PREP inhibitors
have been published in the recent 4-5 years. Overall, it seems that the belief that PREP
inhibitors could be potential cognition enhancers has dissipated.
The ability of KYP-2047 (5 mg/kg i.p.) to prevent scopolamine-induced (0.4. mg/kg i.p.)
amnesia in a radial-arm maze was examined in young and old rats (Peltonen et al., 2010).
KYP-2047  had  no  effect  on  the  memory  of  either  age  group,  but  when  given  without
scopolamine, it slightly increased the maze motility of young rats and decreased the
motility of old rats through some unknown mechanism.
The effect of subchronic administration of rosmarinic acid, a non-competitive PREP
inhibitor (with a relatively high IC50 value of 63.7 μM), was tested in the Morris water maze
in rats, and an enhancement in spatial memory was reported (Park et al., 2010). However,
the brain pharmacokinetics and penetration of rosmarinic acid have not been characterized.
It does seem unlikely that one could achieve sufficient brain penetration to reach
pharmacologically active brain concentrations of rosmarinic acid since the compound
possesses 13 hydrogen bond acceptors and donors and has a high polar surface area (145
Å2). Once the total number of donors and acceptors exceeds 8-10 and polar surface area 100
Å2, the transport of a drug across the blood-brain barrier (BBB) is expected to be minimal
(Pardridge, 2005).
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Table 3. Effects of PREP inhibitors on behavioral parameters.
 = improved performance;  = no effect; mo = month-old; NA = not applicable
PREP
inhibitor
Treatment
(mg/kg)
Animal
age
Behavioral
test(s)
Memory
impairment
Result
(dose)
Reference
JTP-4819 1, 3, 10
p.o. single
 Rat
NA
Passive
avoidance
Scopolamine
0.5 mg/kg s.c.
 3, 10
retention
 1, 3
acquisition
Toide et
al., 1995a
JTP-4819 0.01, 0.1, 1
p.o. 7 days
 Rat
2,5 mo
Passive
avoidance
Middle cerebral
artery occlusion
 0.1, 1
 0.01
Shinoda et
al., 1996
JTP-4819 0.1, 0.3, 1, 3
p.o. 7 days
 Rat
2,5 mo
Morris water
maze
Middle cerebral
artery occlusion
 1

0.1,0.3,3
Shinoda et
al., 1996
JTP-4819 0.3, 1, 3
p.o. 20 days
 Rat
3 mo
vs. 24
mo
Morris water
maze
Age  1
 0.1, 3
Toide et
al., 1997
JTP-4819 0.3, 1, 30 p.o.
34-41 days
 Rat
NA
Eight-arm radial
maze
Dorsal
hippocampal lesion
 3
 0.3, 1
Miyazaki et
al., 1998
JTP-4819 0.3, 1, 3, 10
p.o. 15 days
 Rat
2,5 mo
Morris water
maze
Ibotenate lesion of
Nucleus basalis
magnocellularis
 1, 3
 0.3, 3
Shinoda et
al., 1999
KYP-2047 5
i.p. single
 Rat
3 or 8
mo
8-arm radial
maze
Scopolamine
0.4 mg/kg i.p.
 Peltonen et
al., 2010
S 17092 10
p.o. single
Aged
mice
2-choice
discrimination
task
Age  Marighetto
et al., 2000
S 17092 0.01-30
i.p. single
Rat
NA
Passive
avoidance
Scopolamine
0.3 mg/kg s.c.
 3-30 Morain et
al., 2002
S 17092 10 p.o.
7 days b.i.d
 Mouse
3-5 mo
Elevated Y-
maze
Scopolamine
0.3 mg/kg s.c.
 Morain et
al., 2002
S 17092 1, 3, 10, 30
p.o.
single or 7
days
Rat
NA
Social
recognition test
 single
dose
 7 days
10 mg/kg
Morain et
al., 2002
S 17092 1, 3, 10
p.o. 7 days

Monkey
adult
Delayed
response,
alternation,
matching-to-
sample, visual
discrimination
Chronic low dose
(0.075 mg/kg i.v.)
MPTP
 3
 1, 10
Schneider
et al., 2002
ZTTA 6
p.o. single
 Rat
2 mo
Three-panel
runway task
Cerebral ischemia  Shishido et
al., 1996
ZTTA 10
p.o.4 days
 Rat
2 mo
Passive
avoidance
Basal forebrain
lesion
 Shishido et
al., 1998
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2.2.5 Peripheral diseases
Chronic airway inflammatory diseases
Chronic obstructive pulmonary disease (COPD) is a term referring to two separate
chronic lung disorders: chronic obstructive bronchitis with obstruction of small airways,
and emphysema with enlargement of air spaces and destruction of lung parenchyma, loss
of lung elasticity, and closure of small airways (see Barnes, 2000). It is one of the most
prevalent and fatal diseases in the world, and the World Health Organization (WHO)
predicts that COPD will rise from the 6th most common cause of death to 3rd place by 2020
(Lopez and Murray, 1998). Furthermore, this prediction may well be an underestimate,
since COPD most likely contributes to other common causes of death. In the developed
countries,  cigarette  smoking  is  the  leading  cause  for  COPD,  but  in  the  less  developed
countries also other environmental pollutants, such as wood smoke, are important sources
(Dennis et al., 1996). It is also claimed that genetic factors are important in the development
of COPD (Silverman et al., 1998).
The pathogenesis of COPD is complex, but one key feature is a chronic neutrophilic
airway inflammation occurring in the peripheral airways (bronchioles) and lung
parenchyma (see Barnes, 2000). Cigarette smoke and other irritants initiate an inflammatory
immune response where airway epithelial cells and macrophages release inflammatory
mediators and chemoattractants such as tumour necrosis factor (TNF), interleukin-8 (IL-8)
and  a  tripeptide  PGP.  These  chemoattractants  trigger  the  migration  of  neutrophils  to  the
site of inflammation. Activated neutrophils and macrophages release multiple proteinases
such as matrix metalloproteinases 8 and 9 (MMP-8 and MMP-9) that break down
connective tissue (e.g. collagen)  in  the  lung  parenchyma,  which  in  turn  leads  to  tissue
destruction, emphysema and mucus hypersecretion.
PREP may be involved in the inflammation process that is a characteristic of COPD, and
also in other chronic airway inflammatory diseases such as cystic fibrosis (CF) (Gaggar et
al., 2008; Braber et al., 2011).  Cigarette smoke or other noxious stimuli can act on airway
epithelial  cells  such  that  lung  collagen  is  cleaved  by  MMP-8  and  MMP-9  into  smaller
peptide fractions, which can act as substrates for PREP (Gaggar et al., 2008). PREP cleaves
these fractions into PGP, which has been shown to be an important neutrophil
chemoattractant both in vitro and in vivo (Pfister et al., 1998; Weathington et al., 2006).
Interestingly, PREP seems to be the only protease that can cleave PGP from the collagen
fragments (an often repeated PPGP sequence) generated by MMP-8 and MMP-9 (Gaggar et
al., 2008). The release of PGP leads to continuous recruitment of neutrophils to the
inflammation area, which subsequently releases proteases and again, PGP (Figure 3).
Earlier, PREP had been associated with inflammatory processes in only a few studies. PREP
activity was found to be increased in the knee joint synovial membrane of patients with
rheumatoid arthritis (Kamori et al., 1991). The mechanism of this pro-inflammatory role has
been unknown, but on the basis of the above recent findings, it may have been attributable
to PGP and neutrophil mediated inflammation.
Since PREP seems to play an important role in the release of PGP and thus, in the chronic
neutrophil mediated inflammatory response, PREP inhibitors may represent a novel
therapeutic approach to the treatment of COPD, CF or other chronic inflammatory
disorders. Theoretically, PREP inhibitors might be able to interrupt the inflammatory
cascade by preventing the formation of PGP from collagen. Indeed, the production of PGP
from  collagen  in  the  sputum  of  CF  patients  has  been  prevented  with  the  PREP  inhibitor
ZPP in vitro (Gaggar et al., 2008). Moreover, PREP activity and PGP production were found
to be elevated in the sputum samples of CF patients, implicating increased PREP activity
with PGP generation in vivo.
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Furthermore, it has been shown that PREP activity and PGP formation were elevated in
mice lung homogenates after chronic exposure to cigarette smoke in vivo (Braber et al.,
2011), and that intratracheal administration of a combination of MMP-8, MMP-9 and PREP
generated PGP in mice lungs in vivo (Gaggar et al., 2008). Human blood neutrophils are
known to contain PREP, MMP-8 and MMP-9, and they can generate PGP from collagen in
the presence of an inflammatory stimulus (O'Reilly et al., 2009).
An interesting observation was made very recently when it was discovered that ZPP
could antagonize chemokine receptors CXCR1 and 2 (which mediate the proinflammatory
effects of IL-8) and prevents neutrophils migration to IL-8 and PGP, thus blocking two pro-
inflammatory mechanisms in the same pathological pathway (Hardison et al., 2011).
PREP has been considered to be the main enzyme in the release of a tetrapeptide Ac-
SDKP from T4 (see chapter 2.1.7). There is increasing evidence that Ac-SDKP possesses
anti-inflammatory properties (Yang et al., 2004; Sharma et al., 2008). PREP inhibitors can
block Ac-SDKP release in vivo (Cavasin  et  al.,  2004),  but  it  is  not  known  whether  this  is
relevant in terms of inflammation.
Figure 3. A schematic illustration of the involvement of PREP in the chronic neutrophilic inflammation
cascade. Activated neutrophils release MMP-8 and MMP-9, which cleave collagen into smaller (<30 amino
acids)  fragments  (PGPXXX).  These  fragments  are  then  cleaved  by  PREP  into  PGP,  which  then  acts  as  a
neutrophil chemoattractant. This triggers a vicious cycle of increased neutrophil influx, which induces
oxidant injury, releases more proteolytic enzymes and finally leads to chronic airway inflammation and
organ dysfunction. Modified from Gaggar et al. (2008).
Cancer
Elevated  PREP  activity  has  been  found  in  a  number  of  human  lung  tumors,  and  in
malignant prostate and sigmoid carcinomas (Sedo et al., 1991; Goossens et al., 1996).
Furthermore, increased PREP activity has been found in clear cell renal cell carcinoma,
urothelial carcinoma of the renal pelvis and head and neck squamous cell carcinoma
(Larrinaga et al., 2010). PREP has also been associated with cell proliferation by a yet
unidentified mechanism, and PREP inhibitors have been shown suppress the growth of
malignant tumor cells (see chapter 2.1.4 for discussion and references).
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Since cancer progression is dependent on tumor neovascularization, pro-angiogenic
agents are of importance in neoplastic diseases. The levels of the pro-angiogenic
tetrapeptide Ac-SDKP and PREP are elevated in a number of malignant tissues, perhaps
indicative of a contribution for Ac-SDKP and PREP in the pathogenesis of cancer (Liu et al.,
2003; Liu et al., 2010). Interestingly, angiogenesis can be significantly reduced by PREP
inhibition (Myöhänen et al., 2011), suggesting that PREP inhibitors could have beneficial
effects in anti-tumor therapy.
PREP has been shown to play a key role in the release of an extracellular neutrophil
chemoattractant, PGP (see above). PGP attracts activated neutrophils, which have been
shown to have an important role during cancer progression (Noel et al., 2008). Activated
neutrophils subsequently release multiple proteinases, such as MMPs, that degrade
components (e.g. collagen) of the extracellular matrix. MMPs are central regulators in the
complex tumor ecosystem composed of  cancer  cells,  blood or  lymphatic  endothelial  cells,
pericytes, smooth muscle cells, fibroblasts, adipocytes, immune and inflammatory cells
(Albini and Sporn, 2007), and they facilitate angiogenesis, tumor cell invasion, and
metastasis (Noel et al., 2008; Roy et al., 2009). The activated PGP-MMPs –pathway in tumor
ecosystem may be associated with the increased PREP activity observed in malignant
tumors. Furthermore, PREP inhibitors can block PGP formation at least in vitro (Gaggar et
al., 2008). Thus, PREP inhibition might offer a novel therapeutic approach for cancer
treatment by blocking the PGP-MMPs –pathway.
Celiac disease
Celiac disease (also known as celiac sprue) is a heritable disorder of the small intestine. It
has a high prevalence of 1:100-1:50, but even this may be an underestimate because many
patients have atypical symptoms or none at all (see Farrell and Kelly, 2002). The disease is
characterized by an inflammation response to ingested wheat gluten and to similar rye and
barley proteins, leading to destruction of the intestinal villi and a greatly reduced ability to
absorb nutritients. Currently, the only effective treatment for celiac disease is consumption
of a gluten free diet.
Wheat gluten is a mixture of proline-rich gliadin and glutenin polypeptides. When
dietary gluten is proteolyzed by pepsin and pancreatic enzymes, a mixture of thousands of
peptides is released (see Farrell and Kelly, 2002). One peptide generated from -gliadin, a
33-mer peptide, is an exceptionally pro-inflammatory agent and is recognized by mucosal T
cells in the small intestine of celiac disease patients. This peptide could be detoxified in in
vitro and in vivo assays by exposure to a bacterial PREP, suggesting a potential strategy for
oral peptidase supplement therapy for celiac disease (Shan et al., 2002). Indeed, it has been
demonstrated in vitro and in vivo in rats that a two-enzyme cocktail comprising of a
glutamine-specific cysteine protease (EP-B2) that functions under gastric conditions and
bacterial PREP, which acts in concert with pancreatic proteases under duodenal conditions
could accelerate the breakdown of a gluten-rich solid meal. This combination has been
proposed as representing a potent candidate for celiac disease therapy (Gass et al., 2006;
Siegel et al., 2006; Gass et al., 2007), and it has recently entered phase II clinical trials.
However, the 33-mer peptide is actually a relatively potent mammalian PREP inhibitor
and is highly resistant to human intestinal preparations despite their significant
endogenous PREP activity (Garcia-Horsman et al., 2007b). Moreover, a causative role of
PREP in the pathogenesis of celiac disease has been ruled out. It has been suggested that a
mixture of other peptidases are needed to eliminate gliadin-derived toxic peptides in the
human intestine. Interestingly, proteases (including PREP) from germinating wheat can
degrade gliadin into small peptide fragments and reduce its epithelial toxicity in vitro and
ex vivo (Stenman et al., 2009). Thus, PREP may act in concert with other proteases and have
important role in the detoxification of gliadin.
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2.3 SUMMARY OF THE REVIEW OF THE LITERATURE
In recent years, PREP has been associated with a number of physiological and
pathological functions, but the main physiological role of PREP remains unknown. In
particular, current understanding on the role of PREP in vivo is restricted. Interestingly,
some of the proposed novel functions may even be unrelated to PREPs peptidase activity.
Hence, the potential of PREP as a drug target remains elusive.
Since the enzyme was discovered in the 1970’s, the strongest in vitro evidence has linked
PREP with the cleavage of proline containing small peptides. However, despite numerous
attempts using various techniques the in vivo evidence of this role is inconsistent and needs
further investigation. Novel peptidomics assays have identified several interesting
substrate candidates for PREP in vivo, but validation of the reported results will continue in
the future. Furthermore, it seems that the most promising sources for future in vivo research
involve clarifying the roles of PREP in neutrophil mediated inflammation, in -synuclein
aggregation and in cell proliferation and differentiation.
Several PREP inhibitors have entered clinical trials as potential cognition enhancers, but
these  projects  have  failed  for  unknown  reasons.  The  mechanism  of  action  of  PREP
inhibitors on cognition has not been established. Apparently, the PK and PD properties of
current PREP inhibitors in vivo and e.g. their specificities towards PREP are not well enough
characterized. For example, it has not been reliably shown that PREP inhibitors can
penetrate the BBB and reach the intracellular target site in brain. On the other hand, the
effects of PREP inhibitors on neurotransmitter turnover are not known. A well-
characterized pharmacological tool would help the researchers to unravel the physiological
functions of PREP and also to design new potent and safe PREP inhibitors.
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3 Aims of the study
The general objective of this study was to characterize the PK and PD properties of
model PREP inhibitors in the rat, and to evaluate the potential of PREP as a CNS drug
target. The specific aims of this pharmacological study were:
1. To critically review previously reported effects of PREP inhibitors on cognition and
on putative PREP substrates in the brain (I)  in  order  to  provide  a  comprehensive
background for the subsequent studies (III-V).
2. To assess the ability of two model PREP inhibitors, JTP-4819 and KYP-2047, to
penetrate the brain, to reach and to inhibit brain PREP after a single dose treatment
(II).
3. To confirm the positive cognitive effects of PREP inhibitors by evaluating the effect
of KYP-2047 on scopolamine-induced spatial memory impairment in Morris water
maze in young and in old rats (III).
4. To examine the effects of PREP inhibitors on some putative PREP substrates in the
rat brain in vivo. A special emphasis was placed on the extracellular substrate levels,
since the effect of PREP inhibition on the peptide levels in their main site of action is
not known (III, IV).
5. To find a proof of mechanism for the positive cognitive effects observed with various
PREP inhibitors by measuring the effects of PREP inhibitors on the levels of several
neurotransmitters in rat brain (III, IV, V).
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4 Materials and methods
4.1 ANIMALS
Male Han/Wistar rats, supplied by the National Laboratory Animal Centre (Kuopio,
Finland) were housed in stainless steel cages and kept on a 12-h light/12-h dark cycle at an
ambient temperature of 22 ± 1°C. Both young (2-3-month old, n=351) (II-V) and old (8- to 9-
month  old,  n=38)  (III) rats were used in the studies. Animals had free access to pelleted
food (Lactamin R36; Lactamin AB, Södertälje, Sweden) and fresh tap water (Kuopion Vesi,
Kuopio, Finland). Before the experiments, the rats were housed in groups. After installation
of  microdialysis  guides,  the  animals  were  housed  in  individual  cages  (II, IV, V). All
experiments were performed during the lights-on time of the day (between 7.00 am and
7.00 pm).
All procedures with the animals were performed according to the European Community
Guidelines  and  reviewed  by  the  Animal  Ethics  Committee  at  the  University  of
Kuopio/University of Eastern Finland, and approved by the local provincial government or
by the national Animal Experiment Board.
4.2 TREATMENTS
PREP inhibitors JTP-4819 {(S)-2-[[(S)-2-(hydroxyacetyl)-1-pyrrolidinyl]carbonyl]-
N(phenylmethyl)-1-pyrrolidinecarboxamide} and KYP-2047 (4-phenylbutanoyl-L-prolyl-
2(S)-cyanopyrrolidine) (Figure 4) (II-V) were synthesized by Dr. Elina Jarho (University of
Eastern Finland, Kuopio, Finland) as previously described (Venäläinen et al., 2002; Jarho et
al., 2004). The dosing regimens used in the in vivo studies (II-V) are summarized in Table 4.
Figure 4. The chemical structures, molecular weights and inhibitory constants (Ki against pig
PREP) of JTP-4819 and KYP-2047 (Toide et al., 1995a; Venäläinen et al., 2006).
JTP-4819 was dissolved in saline (II, III, V). KYP-2047 was dissolved in saline containing
5% of Tween® 80 due to its low water solubility (II-V). Control animals received the same
amount  of  vehicle  as  the  drug  treated  animals.  Drugs  were  given  intraperitoneally  in  a
volume of 5 or 10 ml/kg.
Chloral hydrate (350 mg/kg i.p., 3.5% solution in saline, Sigma Chemical Co, St. Louis,
USA) was used as an anesthetic (II, IV, V).
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The acetylcholine (ACh) muscarine receptor antagonist, scopolamine hydrobromide
(Sigma Chemical Co), was dissolved in saline and was given in a volume of 10 ml/kg i.p.
(III).  In  order  to  elevate  the  levels  of  ACh in  the  dialysates,  neostigmine bromide (Sigma
Chemical Co) was used as an additive in the perfusate (final concentration 100 nM) (V).
Bacitracin and bovine serum albumin (BSA) (both from Sigma Chemical Co) were used as
additives in the perfusate (IV)  in order to prevent non-specific peptide degradation in the
perfusate and binding to the apparatus, respectively.
Table 4. The treatment groups and doses used in the in vivo experiments (II-V).
1to convert into mg/kg multiply by 0.36; 2to convert into mg/kg multiply by 0.34.
Abbreviations: MWM, Morris water maze; i.p., intraperitoneal; NA, not applicable; NT, neurotensin; SP,
substance P; b.i.d., bis in die (twice daily); ACh, acetylcholine; DA, dopamine, PK, pharmacokinetics; BSA,
bovine serum albumin.
Study Assay Route JTP-48191 KYP-20472 Additional
drugs
II PK i.p. 50 μmol/kg
- Single dose
- Microdialysis (n=5-7/tissue)
- Tissue conc.: (n=4/time
point)
50  μmol/kg
- Single dose
- Microdialysis (n=5-7/tissue)
- Tissue conc.: (n=4/time
point)
III MWM i.p. NA 15  μmol/kg (old rats) (n=12)
3 & 15  μmol/kg (young rats)
- Single dose
(n=14-16)
Scopolamine
0.4 mg/kg
i.p.
NT
SP
i.p. 9 & 27  μmol/kg
- Single dose (n=6)
- 10 days (b.i.d.) (n=5)
9 & 27  μmol/kg
- Single dose (n=6)
- 10 days (b.i.d.) (n=5)
IP3 i.p. 9  μmol/kg
- 2,5 days b.i.d. (n=8)
NA
IV NT
SP
i.p. NA 50  μmol/kg
- Single dose (NT: n=5)
(SP: n=4)
Bacitracin
(0.03%)
BSA (0.2%)
in perfusate
V ACh i.p. 50  μmol/kg
- Single dose (n=9)
50  μmol/kg
- Single dose (n=8)
Neostigmine
(100 nM) in
perfusateRetro-
dial.
In perfusate
12.5 μM (n=5)
37.5 μM (n=5)
125 μM (n=3)
(× 60min×1.5μl/min)
In perfusate
12.5 μM (n=4)
37.5 μM (n=5)
125 μM (n=3)
(×60 min×1.5μl/min)
DA i.p. 15  μmol/kg
- Single dose (n=3)
50  μmol/kg
- Single dose (n=6)
15  μmol/kg
- Single dose (n=4)
50  μmol/kg
- Single dose (n=7)
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4.3 PHARMACOKINETIC STUDIES
4.3.1 In vitro permeability assay (II)
A primary bovine brain microvessel endothelial cell (BBMEC) model was used to assess
the in vitro brain  permeability  of  the  two studied PREP inhibitors.  BBMECs were isolated
based on the method described earlier (Audus and Borchardt, 1987; Audus et al., 1996). The
cells were cultured and the permeability assays were conducted as described earlier
(Hakkarainen et al., 2010). Drugs were dissolved in Ringer’s solution, and the initial drug
concentration in the donor chamber was 20 μM. JTP-4819 and KYP-2047 sample
concentrations were measured using an LC-MS method (see chapter 4.5.2). The radiotracer
samples (low permeability reference compound [14C]sucrose and high permeability
reference compound [14C]diazepam) were analyzed by liquid scintillation counting (1450
MicroBeta Trilux, Wallac, Finland) after the addition of 500 μl scintillation cocktail
Optiphase, Wallac (Milton Keynes, UK).
4.3.2 Pharmacokinetic microdialysis in anaesthetized rats (II)
The microdialysis guide cannulas (MAB 6.10.IC, AgnTho’s AB, Lidingö, Sweden) were
implanted stereotaxically into the frontal cortex (coordinates from bregma: AP 3.2 mm; L
+0.8 mm; DV -2.5 mm), hippocampus (AP -6.0 mm; L -5.5 mm; DV -3.8 mm) and striatum
(AP +0.5 mm; L -3.0 mm; DV -3.8 mm) (Paxinos and Watson 2007) under anaesthesia. After
a one week recovery period, the rats were again anaesthetized and microdialysis probes
(MAB 9.10.3/4; 3 mm exposed membrane in the cortex and hippocampus, 4 mm exposed
membrane in the striatum, 6 kDa cut-off, AgnTho’s AB) were inserted into each brain area.
An intravenous microdialysis probe (MAB 11.20.10; 10 mm exposed membrane, 6 kDa cut-
off, AgnTho’s AB) was inserted into the left femoral vein, and all probes were perfused
with  Krebs  Ringer  solution  (consisting  of  138  mM  NaCl,  1  mM  CaCl2, 5 mM KCl, 1 mM
MgCl2 ·  6H2O,  11  mM  NaHCO3,  1  mM  NaH2PO4 ·  H2O, and 11 mM D-Glucose, pH 7.4)
(Benveniste and Hüttemeier, 1990) at a flow rate of 2 μl/min. The probes were washed out
for 80 min before the drug administration, and the dialysate was collected in twenty-minute
fractions for 6 hours into polypropylene vials (AgnTho’s AB). The samples were stored at -
80 °C until analyzed. After the termination of each microdialysis experiment, the correct
probe placement in the brain was assured (Figure 5).
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Figure 5. A schematic illustration of the microdialysis guide cannula and probe placement sites as
measured relative to the bregma (II, IV, V). The placement sites in the frontal cortex, hippocampus and
striatum are shown in A, B, and C, respectively. The stained section demonstrating the tissue damage
caused by the probe implantation (circled) in striatum is shown in D. After the termination of each
microdialysis experiment, the rats were decapitated and the brains were rapidly removed and frozen in
cooled isopentane. The brains from randomly selected rats were cut into 30 μm slices with a cryostat
(Bright Instruments, Huntingdon, England), and the sections were stained with 0.5% cresyl violet as
described by Paxinos and Watson (2007). The sizes of the guides and probes are in a true relation to the
brain size. Modified from Paxinos and Watson (2007) with permission from Elsevier Ltd.
4.3.3 Determination of plasma and brain tissue levels of JTP-4819 and KYP-2047 (II)
The rats were anaesthetized and treated with either KYP-2047 or JTP-4819. At pre-
determined time points (10, 30, 60, 120, 180 and 300 min), the brains were made rather
bloodless by a 3-min transcardial perfusion with 0.1 M phosphate buffered saline. Samples
from out flowing blood were collected into K3EDTA tubes (Vacuette, Greiner Bio-one,
Frickenhausen, Germany) and the plasma was separated by centrifugation (1500 × g, 10
min, +4 °C). Finally, the rats were decapitated and the brains were cut sagittally into two
halves; one half being used for the determination of PREP inhibitor concentrations, and the
other used for the PREP activity assay (see chapter 4.5.1).
The brain tissue samples were homogenized on ice in 1:4 w/v of ultrapure water
containing a structural analogue of JTP-4819 and KYP-2047, PREP inhibitor KYP-2153 {(R)-
N-benzyl-5-((S)-2-cyanopyrrolidine-1-carbonyl)cyclopent-1-enecarboxamide}, as an internal
standard. Then, acetonitrile (1:11 w/v) was added to precipitate proteins and the mixture
was centrifuged (16000 × g, 10 min, +4 °C). The PREP inhibitor concentration in the
supernatant was analyzed by an LC-MS method (see chapter 4.5.2).
A B
C D
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JTP-4819 and KYP-2047 were extracted from the plasma samples using protein
precipitation. An aliquot (100 μl) of each plasma sample was mixed with 10 μl of perchloric
acid (30 %) and 50 μl of internal standard solution (KYP-2153). Then, 200 μl of ice-cold
acetonitrile was added and carefully mixed. After centrifugation (11000 × g, 10 min, +10 °C),
the PREP inhibitor concentration in the supernatant was analyzed by an LC-MS method
(see chapter 4.5.2).
4.4 PHARMACODYNAMIC STUDIES
4.4.1 Morris water maze (III)
The effect of PREP inhibition on long-term spatial memory was tested in the Morris
water maze (Stewart and Morris, 1993) with the modification described by Pitkänen et al.
(1995). A circular fiberglass tank, 160 cm in diameter, was filled with tap water (20 ± 2 °C).
The platform (10 cm in diameter) was placed in a permanent location in one quadrant of the
pool, and the water surface was set at 1.5 cm above the platform. Thirty min after the
administration of a PREP inhibitor (or vehicle) and scopolamine, the rat was placed into the
water, and the swimming path was recorded with a video camera. The trial lasted until the
rat found the platform or 70 s had elapsed. The rat was placed onto the platform for 10 s,
unless it was not already on it. The animal was transferred to a cage for 30 s to recover. The
trial was repeated 3 times in sequence. In each trial, the starting point varied. However, for
each  rat,  the  procedure  was  the  same  during  each  day.  One  test  series  consisted  of  3
trials/animal/day over 5 days. The path length, the swimming time and the speed were
calculated.
4.4.2 Microdialysis of endogenous compounds in conscious rats (IV, V)
The rats were anaesthetized and an intracerebral guide cannula (CMA12, CMA
Microdialysis, Solna, Sweden) (IV)  or  MAB  6.10.IC,  AgnTho’s  AB)  (V) was implanted
stereotaxically into the striatum (AP +0.5 mm; L -3.0 mm; DV -3.8 mm from bregma)
(Paxinos and Watson 2007). The animals were allowed to recover from the surgery for 5-6
days.
One h (IV)  or  12  h  (V) before the baseline collection, the animals were moved to the
microdialysis bowls (CMA 120, CMA Microdialysis), and the microdialysis probes CMA12
Elite (4 mm exposed membrane, 20 kDa cut-off) (IV) or MAB 9.10.4 (4 mm exposed
membrane, 6 kDa cut-off, AgnTho’s AB) (V) were inserted into the striatum. The probes
were perfused with calcium enriched Ringer’s solution (138 mM NaCl, 1.3 mM CaCl2,  5
mM KCl, 1 mM MgCl2 · 6H2O, 11 mM NaHCO3, 1 mM NaH2PO4 ·  H2O,  and  11  mM D-
glucose, pH 7.4) (Benveniste and Hüttemeier, 1990) at a flow rate of 5 (IV) or 1.5 (V) μl/min.
0.2% (m/v) bovine serum albumin and 0.03% (v/v) bacitracin were added to the perfusate
(IV).
In the ACh study, the perfusate was changed to Ringer’s solution containing 100 nM of
neostigmine after the 12 h wash out period and nine 20 min baseline samples were collected
(V).  In  the  DA  study  (V), four 20 min baseline samples, and in the neuropeptide studies
(IV), three 20 min baseline samples, were collected.
After a stable baseline had been attained, the appropriate PREP inhibitor was
administered either intraperitoneally (IV,  V)  or  by  retrodialysis  (V) via the microdialysis
probe (see Table 4 for dosing details). The dialysate was collected for 4 (IV) or 5 h (V) as 20-
min fractions.
In the DA study (V), 5 μl of antioxidant solution (containing 1mM of oxalic acid, 0.1 M of
acetic acid and 3.0 mM of cysteine in water) were added to the sample tubes to prevent DA
oxidation.
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All dialysates were immediately frozen (-20 °C) and stored at -80 °C until analyzed. After
each  PD  microdialysis  experiment,  the  correct  probe  placement  in  the  brain  was  assured
(Figure 5).
4.4.3 Determination of the total tissue levels of NT, SP and IP3 (III)
At appropriate time points after the drug administration, the rats were sacrificed by
decapitation and the brains were rapidly removed and dissected (frontal cortex,
hippocampus and hypothalamus) and frozen in liquid nitrogen. Each brain region was
homogenized in +90 °C 1 M acetic acid (1:40 w/v) and incubated in +90 °C for 5 min. After
cooling, the homogenates were centrifuged at 12000 × g and +4 °C for 20 min. Frozen
supernatants were freeze-dried and the remaining sediments were dissolved in the assay
buffers delivered with the ELISA kits (see chapter 4.5.3).
For  the  IP3 assay, rats were decapitated 1 h after the last dose of JTP-4819, and the
hippocampus and cortex were dissected and frozen until analyzed. Then, the samples were
homogenized in ice cold perchloric acid (20%) (1:20 w/v) and centrifuged (2000 × g, +4 °C
for 15 min). The supernatants were titrated to pH 7.5 (±0.1) with 1.5 KOH (in 60 mM
HEPES), and again centrifuged (2000 × g, +4  °C for  5  min)  to  remove precipitated KClO4.
The IP3 contents of the supernatants were assayed as described in chapter 4.5.4.
4.4.4 In vitro specificity screening (V)
The in vitro binding of JTP-4819 and KYP-2047 to 70 pharmacological targets was
assayed commercially (GenSEPII profile, Caliper Life Sciences, Hanover, USA). The binding
assays were carried out in duplicate at a concentration of 10 μM.
The inhibitory effects of JTP-4819 and KYP-2047 against several serine proteases and
proline-specific proteases were assessed with colorimetric or fluorometric standard
methods (see V; Table 2).
4.5 ANALYTICAL PROCEDURES
4.5.1 PREP activity assay (II)
The brain PREP activity in the perfused brain samples was measured as described earlier
using Suc-Gly-Pro-AMC as the PREP substrate (Venäläinen et al., 2006). The formation of
AMC was measured using a Victor2 fluorescence plate reader (PerkinElmer Inc., Waltham,
USA) at the excitation and emission wavelengths of 360 and 460 nm. The protein
concentrations were determined with a Bio-Rad protein assay kit. The PREP activities were
calculated as pmol AMC × min-1 × mg-1 protein and expressed as a percent of the activity in
vehicle treated control animals.
4.5.2 Assay of JTP-4819 and KYP-2047 levels (II)
KYP-2047 and JTP-4819 levels in the in vitro permeability samples, brain and blood
microdialysates,  and  tissue  samples  were  quantified  by  a  liquid  chromatography-mass
spectrometry  (LC-MS)  method.  The  LC-MS  system  consisted  of  an  Agilent  1200  Series
Rapid Resolution LC System (Agilent Technologies, Waldbronn, Germany) coupled with
an atmospheric pressure chemical ionization (Finnigan Ion Max APCI) linear ion trap mass
spectrometer (Finnigan LTQ, Thermo Electron, San Jose, USA). The sample was injected
onto an HPLC column (Zorbax SB-Phenyl Narrow Bore RR column 2.1 × 100 mm, 3.5 μm)
(Agilent Technologies, Palo Alto, USA) using a gradient elution at a flow rate of 0.2 ml/min.
The mobile phase consisted of formic acid (0.1 %, v/v) in water (A) and formic acid (0.1 %,
v/v) in methanol (90 %) (B). Selected reaction monitoring (SRM) was used and the following
transitions were monitored: m/z 340  244 for KYP-2047, m/z 360  231 for JTP-4819, and
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m/z 324  228 for the internal standard KYP-2153. The divert valve was programmed to
allow flow into the mass spectrometer from 1.5 to 8 min of each run.
4.5.3 Neuropeptide immunoassays (III, IV)
The whole tissue concentrations of NT and SP in the frontal cortex, hippocampus and
hypothalamus were assayed with commercial ELISA kits, distributed by R&D Systems Inc.
(Minneapolis, USA) and Phoenix Pharmaceuticals (Belmont, USA), respectively (III).
In order to measure NT and SP levels in the brain microdialysates, highly sensitive RIAs
were set up (IV). In each assay, ten-point standard curves were constructed for either NT or
SP by using known amounts of synthetic peptide (all RIA reagents from Phoenix
Pharmaceuticals, unless otherwise stated). Samples were incubated with NT- or SP-
antiserum, 125I labeled NT or SP and RIA buffer for 72 h at 4 °C. Antibody-bound
radioligand was separated from unbound radioligand by addition of  goat  anti-rabbit  IgG
serum and normal rabbit serum. After 2 h incubation in room temperature and
centrifugation (2000 × g for 20 min at room temperature), the supernatant was carefully
aspirated. Scintillation fluid (Optiphase HiSafe2, Perkin Elmer Inc.) was added and the
bound radioactivity was counted in a liquid scintillation counter (1450 MicroBeta Trilux,
Wallac). Samples either without standards or without antibodies were incubated
simultaneously to measure maximal tracer binding and non-specific binding, respectively.
The acceptability of each assay run was controlled by using quality control (QC) samples
at low, medium and high analyte concentration levels. The assay was accepted when 2/3 of
the QC samples were within 15% of their respective nominal values. QC samples were
prepared and analyzed on the basis of the FDA Bioanalytical Guidance for Industry (2001).
In addition, a precision profile was determined for both analytes in order to assess the
optimal concentration working ranges for the immunoassays (Figure 6) (Lee et al., 2006). In
the working range of the assay the intra-assay coefficient of variation was less than 10%.
The detection limits for both RIAs were 1.2 fmol per 100 μl sample.
According  to  the  manufacturer,  the  NT  antibody  displays  no  cross-reactivity  with  SP,
kinetensin or bombesin. Similarly, the SP antibody is claimed to exhibit no cross-reactivity
with neurokinin B, somatostatin and physalaemin, but 100% cross-reactivity with SP
fractions 2-11, 3-11, 4-11, and 5-11, a 5% cross-reactivity with fraction 6-11, and minor cross-
reactivity (<0.5%) with fraction 7-11, neurokinin A and endothelin-1. The NT and SP
antibodies exhibited no appreciable cross-reactivities to any of the components of the
Ringer’s solution used in the study.
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Figure 6. The precision profiles and sample calibration curves of NT (left column) and SP (right column)
radioimmunoassays. The precision profile represents the plot of the coefficient of the variation (CV) of the
back calculated calibrator concentration vs. the nominal calibrator concentration. The optimal working
range  of  an  assay  is  between  the  solid  lines  where  the  intra-assay  CV<10%.  The  linear  ranges  of  the
standard curves are marked with dotted lines. The precision profile shows whether an assay is capable of
measuring the analyte of interest in a predetermined concentration range. It also illustrates that the linear
portion of the calibration curve does not always define the optimal working range of an assay.
4.5.4 IP3 receptor binding assay (III)
Concentrations of IP3 in  hippocampus  and  cortex  were  assayed  with  a  commercial D-
myo-inositol-1,4,5-trisphosphate [3H]  radioligand  binding  assay  kit  (TRK  1000,  Amersham
Biosciences, Buckinghamshire, UK).
4.5.5 Assay of ACh and DA levels (V)
ACh levels in the microdialysates were measured with a highly sensitive liquid
chromatography/tandem mass spectrometry (LC/MS/MS) method described by Keski-
Rahkonen  et  al.  (2007).  DA,  HVA  and  DOPAC  levels  in  microdialysates  were  measured
with high performance liquid chromatography coupled with electrochemical detection
(HPLC-ECD) as described by Piepponen et al. (2002).
4.6 DATA ANALYSIS AND STATISTICS (II-V)
4.6.1 Microdialysis experiments (II, IV, V)
The concentrations of JTP-4819 and KYP-2047 in blood and brain microdialysates were
corrected with in vivo recovery values using the retrodialysis by drug approach (II) (Bouw
and Hammarlund-Udenaes, 1998). The probes (n=4/probe type/drug) were perfused with
Ringer’s solution containing JTP-4819 or KYP-2047 (Cin= 1 μM). Eighty min after the probe
insertion the retrodialysis was initiated, and after a 20 min stabilization period, five
consecutive  samples  in  fractions  of  20  min  were  collected.  The in vivo recovery was
calculated from the last three samples with the Equation 1
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where R is the in vivo recovery, Cin is the concentration of JTP-4819 or KYP-2047 in the
perfusate and Cout is the concentration in the dialysate. The unbound drug concentrations in
the brain extracellular fluid (ECF) and blood were then calculated with the Equation 2
where C is the in vivo recovery corrected concentration in the tissue, Cout is the measured
concentration in the dialysate and R is  the in vivo recovery value for the corresponding
probe type and tissue. The values of the area under the time-concentration curve (AUC0-
300min; min × μM) were calculated from the individual data with the trapezoid rule using
GraphPad Prism 4.03 software (GraphPad Software, San Diego, CA, USA). The
pharmacokinetic parameters (Cmax,  tmax,  t) were calculated from the individual time-
concentration vs. time data sets based on a one-compartment model using the WinNonlin
Professional v5.0.1. software (Pharsight Corporation, Mountain View, CA, USA) (II).
In the ACh, DA, NT and SP microdialysis studies, the mean of the last three (IV) or four
(V) baseline samples was calculated for each animal as a baseline value (=100%) and the
changes in the extracellular transmitter levels after PREP inhibitor or vehicle treatment
were expressed as a percentage of this value. The transmitter levels were not corrected for
recovery.
The AUC (min × % of baseline) for each animal was calculated with the trapezoid rule
from the time of the drug administration to the end of the dialysis (0-240 min) using
GraphPad Prism 4.03 software (GraphPad Software) (IV). Peaks above the baseline (100%)
were regarded as positive areas, and peaks below the baseline were regarded as negative
areas, and the reported AUC values were calculated as the net area between positive and
negative peaks.
4.6.2 Pharmacokinetic-pharmacodynamic relationship
The relationship between the total blood concentration or total brain tissue concentration
(C) of JTP-4819 or KYP-2047 and brain PREP activity (E) was determined after a single
intraperitoneal dose of 50 μmol/kg i.p. with the Equation 3
(Holford and Sheiner, 1981).The brain PREP activities (pmol × min-1 ×  mg-1) were plotted
against the corresponding blood or brain concentration values (nM). The baseline PREP
activity (E0), maximum attainable PREP inhibition (Emax) and the concentration producing
50% of the maximum attainable PREP inhibition (EC50) were fitted as free parameters using
GraphPad Prism 5.03 software.
4.6.3 Statistical analyses (II-V)
A two-tailed Student’s t-test was used to test the statistical significance of differences
between  two  groups  in  the  PK  studies  (apparent  permeability  [Papp]values in the BBMEC
model and the AUC0-300min,  Cmax,  tmax and t values in microdialysates) (II),  and in  the  NT
and  SP  microdialysis  studies  to  compare  the  effect  of  KYP-2047  vs.  control  on  AUC0-240min
values (IV). Tests were performed using GraphPad Prism 4.03 software.
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The water maze data were analyzed using one-way analysis of variance (ANOVA)
followed by Bonferroni post hoc multiple group comparison test (III).
A mixed model was constructed to assess the difference between groups in ACh and DA
levels at different time points (time, group and their interaction as fixed effects and rat
number as random effect) using SPSS for Windows 14.0.1 software (SPSS Inc., Chicago,
USA) (V).
The differences with p-values <0.05 were considered as statistically significant.
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5 Results
5.1 PHARMACOKINETICS OF JTP-4819 AND KYP-2047 (II)
5.1.1 In vitro permeability
Both JTP-4819 and KYP-2047 permeated through the cell monolayer in the BBMEC
model, but the Papp of KYP-2047 was 8.5-fold higher than the corresponding value of JTP-
4819 (Table 5) (p<0.0001).
The Papp value for the low permeability reference compound sucrose was 30.9 ± 4.4 × 10-6
cm/s (n=7). For the high permeability reference diazepam it was 391.0 ± 24.3 × 10-6 cm/s
(n=7), both of which are in agreement with previously reported values (Eddy et al., 1997;
Hakkarainen et al., 2010).
5.1.2 In vivo pharmacokinetics
The PK parameters of JTP-4819 and KYP-2047 after a single dose of 50 μmol/kg i.p. are
summarized in Table 5. The microdialysis data revealed that both JTP-4819 and KYP-2047
penetrated the brain ECF (Figure 7). In the blood, the apparent unbound AUC0-300min values
were almost 7-fold higher for JTP-4819 (p<0.001). In the brain ECF, the unbound AUC0-300min
values of JTP-4819 were 4-6-fold higher (p<0.05) than those of KYP-2047 depending on the
brain area. However, the unbound brain/blood ratio (i.e. the fraction penetrated into the
brain) was maximally 56% higher for KYP-2047 (in the hippocampus), indicating better BBB
penetration of KYP-2047 after single-dose administration.
KYP-2047 showed similar blood-to-brain distribution patterns in the cortex,
hippocampus  and  striatum  as  measured  by  the  unbound  brain/blood  AUC0-300min ratios
(Table 5). In contrast, there was a trend (ns) towards differences in the drug concentrations
between the brain areas in JTP-4819 treated animals; highest concentrations were measured
from the cortex (Figure 7).
Figure 7. The unbound concentrations of JTP-4819 and KYP-2047 in the rat blood, cortex, striatum and
hippocampus after a single intraperitoneal dose of 50 μmol/kg (n=5-7/tissue/compound).
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The unbound concentration of KYP-2047 in the brain ECF correlated with its unbound
blood concentration (correlation coefficient 0.89, p<0.0001 in each brain area), evidence of a
homogenous blood-to-brain distribution pattern to all brain areas regardless of the amount
of free drug in the blood (Figure 4 in II). In contrast, the unbound concentrations of JTP-
4819 in the brain ECF were dependent on the corresponding unbound blood concentration
only in the cortex and hippocampus (correlation coefficients 0.83, 0.73, respectively,
p<0.0001), but not in the striatum (correlation coefficient 0.17, p=0.13). This is evidence of
non-homogeneity in the regional distribution of JTP-4819 after a single intraperitoneal dose.
Table 5. The PK parameters (mean ± S.E.M.) of JTP-4819 and KYP-2047 calculated from the
microdialysis, total tissue and BBMEC data.
 1AUC, area under time-concentration curve; 2maximal concentration; 3AUCbrain/AUCblood (calculated from the individual
time-concentration curves for the unbound concentrations and from the group data for the total tissue concentrations);
4apparent values; 5apparent permeability coefficient.
KYP-2047 reached the total maximal plasma concentration early (10 min), whereas the
total Cmax of JTP-4819 was reached 30 min after the treatment (Figure 8). The total plasma
levels of JTP-4819 were substantially higher; the AUC of JTP-4819 was over 3-fold higher
than that of KYP-2047 (Table 5). However, the total Cmax in  the  perfused brain  was 2-fold
higher for KYP-2047 (Figure 8). KYP-2047 achieved the maximal brain concentration faster
than JTP-4819 (brain tmax 10 min vs. 30 min for KYP-2047 and JTP-4819, respectively.
The brain/blood AUC0-300min ratios calculated from the total tissue concentrations were
approximately 30% higher for KYP-2047, which is about the same as the unbound
brain/blood AUC0-300min ratios calculated from the microdialysis data (Table 5).
JTP-4819 KYP-2047
AUC0-300min
1
(min × µM)
Cmax
2
(µM)
Brain/
blood ratio3
AUC0-300min
1
(min × µM)
Cmax
2
(µM)
Brain/
blood ratio3
Unbound
extracellular
concentration
Blood4 1947 ±287 16.7 ± 3.1  285 ± 30 5.01 ± 0.57
Cortex4 206 ± 41 1.78 ± 0.29 0.13 ± 0.02  32 ± 6 0.57 ± 0.12 0.13 ± 0.01
Hippocampus4 128 ± 17 1.05 ± 0.23 0.09 ± 0.01  38 ± 9 0.71 ± 0.19 0.14 ± 0.02
Striatum4 178 ± 53 1.26 ± 0.58 0.10 ± 0.04  42 ± 11 0.72 ± 0.16 0.13 ± 0.03
Total tissue
concentration
Plasma 4230 78.6 ± 14.4  1350 37.0 ± 11.0
Brain 145 1.47 ± 0.47 0.034  60 3.01 ± 1.38 0.045
In vitro
permeability Papp (× 10
6 cm/s) 5 Papp(× 10
6 cm/s) 5
BBMEC 25.4 ± 4.3 213.8 ± 9.0
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Figure 8. The total brain and plasma levels of JTP-4819 and KYP-2047 after a single dose of 50 μmol/kg
i.p. (n=4/time point for both inhibitors).
5.2 PHARMACODYNAMICS OF JTP-4819 AND KYP-2047 (II-V)
5.2.1 Animal weight monitoring
During the 10-day treatment (III), the body weights of the animals were monitored daily
(Figure  9)  to  control  possible  adverse  effects  of  the  compounds  or  vehicle.  No  signs  of
abnormal weight gain, behavior or toxicity were observed during the animal studies (II-V).
Figure 9. The body weight gain (% of initial weight) of the rats during the chronic 10-day b.i.d.
administration of JTP-4819 or KYP-2047 (9 or 27 μmol/kg i.p., n=5/group) (III). Controls received saline
containing 5% of Tween® 80.
5.2.2 Inhibition of brain PREP (II)
The basal PREP activity in perfused rat brain was 1223 ± 86 pmol × min-1 ×  mg-1 (n=8).
KYP-2047 produced a higher degree of brain PREP inhibition than JTP-4819 (Figure 10). In
the KYP-2047 group, the brain PREP activity was fully inhibited 10-60 min after drug
administration. At 300 min, the PREP activity had recovered to a level of 35%.
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JTP-4819 did not produce full inhibition of brain PREP activity at any time point.
Moreover, the interindividual variation was much higher than in KYP-2047-treated
animals. JTP-4819 appeared to have a longer duration of inhibitory action than KYP-2047,
as the degree of inhibition remained unchanged between 180-300 min.
Figure 10. PREP  activity  as  a  function  of  time  in  the  perfused  rat  brain  tissue  after  a  single  dose  (50
μmol/kg i.p.) of JTP-4819 or KYP-2047 (n=4/time point for both inhibitors).
5.2.3 Effect on spatial memory in rats (III)
In the Morris water maze, scopolamine was used to create a learning deficit in the rats. In
old rats, scopolamine-treatment increased the escape path length significantly only on days
1 and 2 as compared to the vehicle-treated animals (p<0.05). In young rats, scopolamine
impaired spatial learning significantly on days 1, 2, 3 and 4 as measured by increased path
length (Figure 11).
In young rats, a low dose (3 μmol/kg i.p.) of KYP-2047 had no effect on the scopolamine-
induced memory impairment on any testing day. However, a higher dose (15 μmol/kg i.p.)
significantly shortened the swimming path length as compared to the scopolamine-treated
animals on days 2 and 4 (p<0.05). Scopolamine-treatment significantly (p<0.05) increased
the swimming time only on day 2 in comparison to the control animals. On the other
testing days, scopolamine increased the swimming times by 10-15 sec/trial, and KYP-2047
(15 μmol/kg) restored this impaired performance to the level of the control animals.
Since the disrupting effects of scopolamine on the water maze performance in the old
rats were seen only on days 1 and 2, the assessment of the anti-amnesic effects of KYP-2047
was limited only to those days. KYP-2047 (15 μmol/kg i.p.) could not alleviate the
disrupting effect of scopolamine on the swimming path length on either day.
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Figure 11. The  effect  of  KYP-2047  on  water  maze  performance  in  old  (left  column)  and  in  young  (right
column) rats. The path length and swimming time represent the group mean (±S.E.M.) of three daily
trials. The drugs were administered intraperitoneally 30 min before the first daily trial. Old rats: Control
n=13; Scop n=13; Scop + KYP-2047 15 μmol/kg n=12. Young rats: Control n=14; Scop n=15; Scop +
KYP-2047 3 μmol/kg n=14; Scop + KYP-2047 15 μmol/kg n=16.
* p<0.05 Scop-KYP-2047 15 µmol/kg vs. Scop; # p<0.05 Control vs. Scop.
5.2.4 Effect on NT, SP and IP3 levels in rat brain (III-IV)
The mean total concentration of NT in the hypothalamus of control animals was 41 ± 7
ng/g wet tissue (n=17) (III). JTP-4819 or KYP-2047 had no significant effect on the NT levels
either after the single or with repeated administration (Figure 4 in III).
In the microdialysis study (IV), the mean baseline value for extracellular NT in the
striatum was 14.4 ± 2.6 fmol/100 μl sample (n=10) (Figure 12). After the i.p. administration,
there was a trend towards decreased NT levels in the control and KYP-2047 groups. A 40-
50% reduction in NT levels was observed 40 min after the intraperitoneal injection of KYP-
2047 (n=5) and vehicle (n=5). In both groups, the AUC net area was clearly negative.
The  mean  concentration  of  the  total  tissue  SP  in  control  animals  varied  between  7  ±  1
(hippocampus) and 133 ± 13 ng/g wet tissue (hypothalamus) (n=17). A single dose of KYP-
2047 or JTP-4819 had no effect on the total tissue SP levels in any of the brain areas
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investigated at either time point (1 and 3 h) (Figure 3 in III). Subhronic 10-day treatment
did not differ from the situation seen after single dosing.
In  the  microdialysis  study  (IV), the mean baseline value for extracellular SP in the
striatum was 1100 ± 80 fmol/100 μl sample (n=8) (Figure 12). The SP levels tended to
increase slightly after intraperitoneal injection with either KYP-2047 (n=4) or vehicle (n=4).
However, this increase was transient, and SP immunoreactivity reverted back to the
baseline values in the next fractions. No significant differences in the net AUC values
between the groups were found, i.e. KYP-2047 did not have any effect.
A subchronic 2.5-day JTP-4819 treatment (9 μmol/kg i.p. b.i.d, n=8) had no effect on the
total tissue IP3 levels in the cortex or hippocampus compared to the vehicle treated animals
(Figure 5 in III).
Figure 12. The extracellular neurotensin and substance P levels (% of mean baseline ± S.E.M.) in the rat
striatum after KYP-2047 treatment (50 μmol/kg i.p.)  as measured by the microdialysis  method. The net
AUC change (min × % of baseline ± S.E.M.) was calculated as the net area between the areas of positive
(above baseline) and negative (below baseline) peaks 0-240 min after the treatment.
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5.2.5 Effect on ACh and DA levels in rat brain (V)
The mean baseline extracellular ACh level in the striatum of the control animals was 12 ±
2 nM (n=8). KYP-2047 had no effect on the ACh levels after its systemic administration
(Figure 13). When administered directly into the brain by retrodialysis, KYP-2047 decreased
the  ACh  levels  by  40-50%  as  compared  to  the  control  group  during  the  60  min  drug
infusion at the two higher concentrations (37.5 and 125 μM), but the difference reached
statistical significance only in the 37.5 μM concentration group (p<0.05). In addition, the
lowest drug concentration (12.5 μM) tended to decrease ACh levels (by ~35%), although
more  slowly.  The  ACh  levels  recovered  slowly  after  the  treatment;  240  min  after  the
termination of the drug infusion, the ACh levels were still 30% below the baseline.
JTP-4819 decreased ACh levels maximally by 25% after the systemic administration
(p<0.05 at 300 min, and p=0.053 at 280 min) (Figure 13). In the retrodialysis, all JTP-4819
concentrations decreased ACh levels by 30-50%. Due to the small group sizes, the
difference in treated vs. control group was statistically significant only at 20 min (12.5 μM)
and 100 min (125 μM). The maximum effect (40-50% decrease) was observed 80-100 min
after the onset of the retrodialysis.
The mean baseline extracellular DA level in the striatum of control animals was 2.7 ± 0.3
nM (n=10). After the lower dose (15 μmol/kg i.p.; n=3-4), the DA levels tended (ns) to
decrease in JTP-4819 treated rats but not in KYP-2047 treated animals, but with extensive
interindividual variations (Figure 14). Maximally this decrease was almost 40% at 300 min
after JTP-4819 administration. After the higher dose (50 μmol/kg i.p.; n=6-7), there was also
a trend (ns) towards decreased DA levels, and it was observed in both treatment groups;
the maximum decrease of approximately 30% was observed at 140 and 240 min after the
administration of KYP-2047 and JTP-4819, respectively. However, DA levels were slightly
decreased (by 10-15%) in control animals as well, indicating that the DA decrease in PREP
inhibitor treated animals was not very significant. There were no differences in DOPAC
and HVA levels between groups after the PREP inhibitor administration at either doses,
and only the normal fluctuation associated with the circadian rhythm was observed
(Castaneda et al., 2004) (Figure 14).
Figure 13. The effects of JTP-4819 and KYP-2047 on the extracellular  ACh levels in rat  striatum after a
single intraperitoneal dose (50 μmol/kg i.p.; n=8-9) or retrodialysis administration for 60 min (gray area;
n=3-5/dose). * p<0.05 vs. Control; $ p<0.05 12.5 µM vs. Control; § p<0.05 125 µM vs. Control; #
p<0.05 37.5 µM vs. Control.
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5.2.6 Specificity of JTP-4819 and KYP-2047 in vitro (V)
The GenSEPII screening profile did not reveal any significant binding of KYP-2047 or
JTP-4819 to the pharmacological targets tested (V; Table 1), i.e. according to the preset
criteria of the GenSEPII profile (the compound should show inhibition of specific
radioligand binding by >50%), no off-targets were found.
At 10 μM, JTP-4819 or KYP-2047 did not exert any significant inhibitory effect against
several serine proteases and proline-specific proteases (V; Table 2). About 20 % inhibition
of lysosomal prolyl carboxypeptidase activity was observed at 10 μM and 50% at 100 μM.
Plasmin was inhibited by about 30% by the 100 μM concentration of KYP-2047.
5.3 PHARMACOKINETIC-PHARMACODYNAMIC RELATIONSHIP
The relationship between the total blood concentration of JTP-4819 or KYP-2047 and the
brain PREP activity is presented in Figure 15. The data fitted the model well (R2=0.89 and
0.93 for JTP-4819 and KYP-2047, respectively). The calculated E0 estimates (1239 and 1219
pmol × min-1 × mg-1 for JTP-4819 and KYP-2047, respectively) were close to the actual value
(1223 ± 86 pmol × min-1 × mg-1) for both compounds. The EC50 value of KYP-2047 was much
lower than that of JTP-4819 (27.3 nM vs. 461 nM, respectively).
Figure 14. Extracellular DA, DOPAC and HVA levels in the rat striatum after a single intraperitoneal dose
(15 or 50 μmol/kg i.p.) of JTP-4819 (triangle), KYP-2047 (square) or vehicle (circle).
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Figure 15. The relationship between the brain PREP activity and the total blood concentration of JTP-4819
or KYP-2047 after a single dose of 50 μmol/kg i.p. The inhibitory Emax model [E= E0-(Emax× C)/(EC50 + C)]
was fitted to the data. Each observation represents a single animal.
The relationship between the total brain tissue concentration of JTP-4819 or KYP-2047
and the brain PREP activity is presented in Figure 16. The data fitted the model well
(R2=0.86 and 0.94 for JTP-4819 and KYP-2047, respectively). The calculated E0 estimates
(1233 and 1220 pmol × min-1 × mg-1 for JTP-4819 and KYP-2047, respectively) were close to
the actual value (1223 ± 86 pmol × min-1 × mg-1). The EC50 value of KYP-2047 was lower than
that of JTP-4819 (1.55 nM vs. 70.4 nM, respectively).
Figure 16. The relationship between the brain PREP activity and the total brain tissue concentration of JTP-
4819 or KYP-2047 after a single dose of 50 μmol/kg i.p. The inhibitory Emax model [E= E0-(Emax× C)/(EC50
+ C)] was fitted to the data. Each observation represents a single animal.
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6 Discussion
6.1 PHARMACOKINETIC STUDIES
6.1.1 Assessment of drug brain penetration in CNS drug discovery
The brain is protected from xenobiotics by a specialized structural and functional
obstacle called the blood-brain barrier (BBB) (Pardridge, 2005). The BBB also efficiently
prevents the passage of many therapeutic agents into the brain. In fact, it has been
estimated that 98% of all small drug molecules do not cross the BBB, and that the transport
of small molecules across the BBB is an exception rather than a rule.
In the development of drugs for CNS diseases,  it  is obvious that one should select lead
molecules that readily penetrate the BBB. However, it is not obvious which parameters best
describe the brain penetration potential of a drug molecule. In general, the brain
pharmacokinetics of a drug can be described by the extent and time (rate) required to reach
brain equilibrium (Hammarlund-Udenaes et al., 2008; Liu et al., 2008). From a PD point of
view, the rate of drug transport is a less crucial parameter than its extent, which better
describes the target site concentration and thus, is the key feature determining the in vivo
potency  of  a  centrally  acting  drug.  In  the  pharmaceutical  industry,  the  extent  of  drug
transport across the BBB has been traditionally described by the total brain-to-blood ratio
(often  referred  to  as  Kp in the literature). However, the use of this parameter has been
criticized,  since  it  strongly  depends  upon  the  drug  binding  in  plasma  and  especially  the
non-specific binding in brain. Thus, Kp often leads to overestimation of CNS drug exposure
(Pardridge, 2003; Pardridge, 2004; Liu et al., 2008) and it is difficult to reliably assess the
brain penetration on the basis of Kp alone (Doran et al., 2005).
On  the  basis  of  the  classical  free-drug  hypothesis,  it  is  the  unbound  fraction  of  a  drug
that exerts the pharmacological effects. Therefore, a better parameter than Kp to describe the
extent of brain penetration is the unbound brain-to-blood ratio which can be measured with
in vivo microdialysis (II) (Hammarlund-Udenaes et al., 2008). However, not even the
unbound brain-to-blood ratio can estimate the target site drug concentrations if the drug
target is located intracellularly, as is the case with PREP. Currently, there is no established
method available to measure the unbound drug concentrations directly in the intracellular
space, although an indirect experimental technique has been proposed (Friden et al., 2007).
In the present study, the brain penetration of PREP inhibitors was assessed by combining
the total tissue (=Kp) and unbound extracellular measurements. By using this approach, it
was possible to evaluate the distribution of the compounds between the extra/intracellular
compartments in the brain, which is of importance because the target site is intracellular.
Finally,  the  PK  data  was  interpreted  side-by-side  with  the  primary  PD  response  of  the
compounds (i.e. degree  of  brain  PREP  inhibition)  in  order  to  compare  the  true in vivo
potency of the two model drugs.
6.1.2 Challenges in PREP inhibitor brain penetration
Since the targets for the potential therapeutic effects of PREP inhibitors are located in the
CNS, the development of novel PREP inhibitors has focused on molecules that best inhibit
brain PREP. The PREP enzyme concentration in the mammalian brain is high (in pig brain
homogenate approximately 30 nM according to Venäläinen et al., 2002), and therefore high
target-site inhibitor concentrations are also required to achieve full brain PREP inhibition.
Therefore,  a  successful  brain  targeted  PREP  inhibitor  should  have  the  ability  to  cross  the
BBB with ease, a Ki value preferably in the nanomolar range and an appropriate duration of
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action in the brain. The latter two of these properties are usually not a problem since most
known potent PREP inhibitors, such as JTP-4819 and KYP-2047, are tight-binding inhibitors
with slow dissociation rates from the active site of the enzyme (Venäläinen et al., 2002;
Venäläinen et al., 2006). In contrast, adequate brain penetration may be difficult to achieve
since most known PREP inhibitors are substrate-like short pseudopeptides that have a poor
potential for crossing the BBB, mostly due to their low lipophilicity (Lawandi et al., 2010).
Earlier,  the brain penetration of PREP inhibitors has been evaluated on the basis of the
degree  of  PREP  inhibition  in  animal  brain  extracts,  but  no  reports  on  the  actual  drug
concentrations in the brain or in the target site have been published. However, the fact that
these molecules can inhibit brain PREP ex vivo does not prove that they were actually
transported into the brain; inhibitors may have been trapped into the cerebral blood, and
they may have reached the target enzyme only after brain homogenization. Alternatively
they may have passed through the BBB to some extent (if the driving force of the unbound
drug in blood is high), but are unable to pass through the neuronal cell membranes and
accumulate within the brain ECF (Figure 17). Since the target protein PREP is located
intracellularly, it is crucial to estimate the distribution of the inhibitors between blood, the
ECF and brain parenchyma.
Figure 17. A schematic illustration of the blood-brain barrier (BBB) and the brain compartments. In order
to reach and inhibit PREP in the intracellular fluid (ICF) of a neuron, an inhibitor has to pass through the
BBB and the neuronal cell membrane. In the present study, microdialysis (μD) was used to monitor the
unbound extracellular PREP inhibitor concentrations in the blood and in the brain ECF. The total tissue
concentrations take into account both the unbound and bound inhibitor fractions in the blood and in the
total brain tissue. If the residual cerebral blood is not removed by perfusion before brain sampling, the
brain samples will contain the drug in plasma as well. This can lead to inaccurate estimations of the drug
levels that have actually penetrated the brain.
6.1.3 Pharmacokinetics of PREP inhibitors
Considering the fact that PREP inhibitors have gained reasonable pharmaceutical
interest during the last few decades and three of them (S-17092, Z-321 and JTP-4819) have
entered clinical trials (Umemura et al., 1997; Umemura et al., 1999; Morain et al., 2002), it is
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surprising that there are no previous published reports about their brain penetration
characteristics. The available PK data is from dog, rat or human plasma.
S-17092 was reported to achieve peak plasma concentration rapidly after oral
administration in rats and dogs (Morain et al., 2002), but the actual drug concentrations
were not presented in the literature. Several peak concentrations were observed after high
oral doses, indicating slow absorption or saturated active transport. The absolute oral
bioavailability was 15% in rats and 4% in dogs, and it tended to increase with higher doses,
an indication of saturated active efflux transport in the intestine, or alternatively, saturated
first pass metabolism. Notably, no reports on the brain tissue levels of S-17092 have been
published.
In humans, the pharmacokinetics of S-17092 was assessed after a single oral dose and
after subchronic 7-day administration (100-1200 mg/day) (Morain et al., 2000). The drug
was well-tolerated, but high interindividual variability in PK parameters was observed. S-
17092 was claimed to be a centrally active substance as it induced statistically significant
modifications in the electroencephalographs (EEG) of the S-17092 treated patients
compared to those treated with placebo, but this cannot be taken as direct evidence of brain
penetration of the compound. Moreover, the EEG modifications were not dose-dependent.
Z-321 was also reported to be well-tolerated in humans (Umemura et al., 1999). After a
single dose of 30-120 mg, the plasma Cmax values varied between 64 and 543 ng/ml (= 0.2-1.9
μM), respectively, and the elimination half life was 1.8 h. With repeated administration (60
mg b.i.d  for  7  days),  the  Cmax values were approximately 100 ng/ml (= 0.3 μM) after each
dose. There are also no preclinical reports on the brain concentrations of Z-321.
Orally administered JTP-4819 (single dose of 30-120 mg or 60 mg three times daily for 7
days) was found to be well-tolerated in healthy male volunteers (Umemura et al., 1997).
The plasma Cmax values of JTP-4819 after 30 and 120 mg were 474-1649 ng/ml (= 1.3-4.6 μM),
and the AUC0-	 values 240-1000 min × μM, respectively. The elimination half life (t) was
about 2 h regardless of the dosage, which parallels the plasma elimination half life observed
in the present study in rats (130 min). The assumption that JTP-4819 penetrates the brain
has been based on the concept that the compound inhibits rat brain PREP ex vivo (Toide et
al., 1995a).
In the present study, the BBB penetration characteristics of JTP-4819 and KYP-2047 were
assessed using in vitro, in vivo and ex vivo methods. The in vitro data showed that the
passive endothelial cell permeability properties of KYP-2047 were remarkably more
favorable than those of JTP-4819. The measured Papp value of KYP-2047 was similar to that
reported for several brain penetrating drugs such as ondansetron, midazolam and
metoprolol (Hakkarainen et al., 2010). In contrast, the Papp value of JTP-4819 was even lower
than that of the low-permeating reference compound, sucrose. This may be a reflection of
the different physicochemical properties of the two compounds; KYP-2047 has a
substantially higher logP (1.6 vs. 0.2), smaller polar surface area (64 vs. 90 Å2), fewer
hydrogen bond donors and acceptors (3 vs. 6) and a slightly lower molecular weight (339
vs. 359 g/mol) than JTP-4819, and all these factors are known to increase passive transport
across the BBB (Pajouhesh and Lenz, 2005; Pardridge, 2005).
These poor cell membrane penetration properties of JTP-4819 were also witnessed in the
in vivo and ex vivo studies. The unbound extracellular levels of JTP-4819 were found to be
almost identical with the total tissue concentrations as estimated by the similar AUC0-300min
values of JTP-4819 in the brain ECF and total brain tissue (Table 5). These results indicate
that the unbound JTP-4819 may have been trapped within the brain extracellular
compartment because of its poor membrane penetration. Thus, JTP-4819 seems to have a
lower potential to reach the intracellular PREP than KYP-2047. This was supported by the
lower degree of brain PREP inhibition obtained with JTP-4819 despite the 4-6-fold greater
extracellular brain levels than those achieved with KYP-2047.
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To compare the true in vivo potency of JTP-4819 and KYP-2047, the relationship between
the total tissue drug concentrations and brain PREP activity was studied. The EC50 value of
KYP-2047 (1.55 nM) was much lower than that of JTP-4819 (70.4 nM) (Figure 16). This
difference in the in vivo potency cannot solely be explained by the slightly different in vitro
potencies of the compounds, since these inhibitors have similar Ki values against PREP
(0.023 nM and 0.055 nM for KYP-2047 and JTP-4819, respectively) (Toide et al., 1995a;
Venäläinen et al., 2006). Therefore, the most likely explanation for the different EC50 values
is the poor ability of JTP-4819 to reach its intracellular target site.
The unbound brain/blood ratio (i.e. the fraction penetrating into the brain) of KYP-2047
was at its greatest 56% higher than that of JTP-4819 (Table 5). This was considered to reflect
the better BBB penetration of KYP-2047 after single dose administration. However, one
could have predicted that the difference in the brain/blood ratio would have been even
greater due to the poor cell membrane penetration properties of JTP-4819. The smaller than
expected difference between the compounds may be explained by the high dose used in
this study; the high dose led to a high unbound JTP-4819 concentration in the plasma,
which  created  a  massive  gradient  force  driving  the  drug  through  the  BBB.  In  general,
however,  it  is  not  desirable  to  increase  systemic  drug  exposure  excessively  to  gain
pharmacologically active brain concentrations. In that sense, KYP-2047 may possess better
safety potential than JTP-4819.
The surprisingly small fraction of KYP-2047 penetrating the brain could also be
explained by the function of the efflux proteins present in the BBB. Efflux transporters, such
as the P-glycoprotein (P-gp), restrict the transport of their substrates from blood into the
brain. This lowers the brain AUC values of a compound, and subsequently the brain/blood
AUC ratio declines. At the moment, it is not known whether KYP-2047 is an efflux protein
substrate. A preliminary calcein-AM study showed that KYP-2047 is not an inhibitor of the
most common BBB efflux transporters, e.g. the  P-gp  and  multidrug  resistance  protein  1
(MRP1) (Hakkarainen et al., unpublished data). However, a compound may be a substrate
even if it does not inhibit the transporters. Thus, the role of efflux proteins in KYP-2047
brain  transport  should  be  studied  more  thoroughly  by  using  for  example  bidirectional
transport assays in vitro.
Because the peripheral microdialysis probe was inserted into the femoral vein, it was
convenient to assess the PK characteristics of the model inhibitors in anaesthetized rats.
Instead, the PD studies were conducted in conscious animals to avoid the disturbing effects
of anaesthetics on transmitter release. Anaesthesia may impair e.g. the hemodynamics of
the animals especially at the end of the experiment when the anaesthesia has been applied
for several hours. This can subsequently alter drug distribution, excretion and metabolism.
However, both inhibitors showed linear elimination throughout the experiments (Figures 7
and 8), indicating that the long-lasting anaesthesia had not been altered the elimination rate
of the compounds.
The predicted clinical dosing of JTP-4819 has been reported to be 1 mg/kg (2.8 μmol/kg),
and based on this value the clinical PK studies were conducted using a dose range of 30-120
mg (corresponding about 1.3-5 μmol/kg) (Umemura et al., 1997). As the current study is the
first report on the brain levels of JTP-4819 in any species, this data offers the first chance to
speculate  on  the  brain  levels  and  the  degree  of  brain  PREP  inhibition  obtained  in  the
human studies. In the rat, the fraction of JTP-4819 absorbed into the brain after a single
dose was 0.034 (calculated from the AUC ratios of total brain tissue and plasma levels).
Should the fraction be the same in humans, the brain AUC0-	 of JTP-4819 achieved after a
single dose of 30-120 mg in humans would have been in the range 8-34 nM × min,
respectively (reported AUC0-	 in plasma 240-1000 nM × min). These levels are
approximately 4-16 times lower than those calculated in the present PK study in the rat.
Despite the much higher drug levels in the rat, it was not possible to achieve more than 85%
PREP inhibition in the rat brain.
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The above calculation raises the question to what degree the human brain PREP would
be inhibited with the predicted clinical dose of 1 mg/kg. To evaluate this problem, it was
decided to study the relationship between the plasma drug concentration and brain PREP
activity in rats using an inhibitory Emax PK-PD  model  (Figure  15).  The  EC50 value  of  JTP-
4819 in the rat was 461 nM. Thus, the peak plasma concentration of JTP-4819 after a dose of
about 1 mg/kg (=60 mg single dose) in the humans was about five times (2500 nM) higher
than the estimated EC50 value in the rat. This calculation suggests that pharmacologically
active brain concentrations of JTP-4819 could have been achieved already at a dose of 1
mg/kg in humans, despite the limited brain penetration of this drug. This is also evidence of
the high in vivo potency of current PREP inhibitors.
Additionally,  there  is  a  US  Food  and  Drug  Administration  (FDA)  guideline  for
calculating the  human equivalent  dose  (HED) based on the  body-surface  area  conversion
factor (BSA-CF) between species (Guidance for Industry for estimating the maximum safe
starting dose in initial clinical trials, 2005). From rat to human the BSA-CF is 6.2, i.e. the
dose used in the preclinical rat study should be divided by 6.2 to obtain HED that produces
the  same  degree  of  effect  as  that  observed  in  the  animals  at  a  given  dose.  In  the  present
study with JTP-4819, HED would have been 17/6.2 mg/kg = 2.7 mg/kg. This value is close to
the highest dose used in the human studies (120 mg single dose/65 kg = 1.8 mg/kg),
indicating that the dose range in the clinical study (Umemura et al., 1997) has been well
justified. However, based on the above calculations, the highest degree of brain PREP
inhibition by JTP-4819 in the human studies has most likely been lower than the 85% that
was observed in the current preclinical study.
The translation of in vivo data from rats to humans is always fraught with difficulties
because of the differences between the species. For example, there are marked differences
in the structure of the BBB in rats and humans. These species-related characteristics can
significantly affect the fraction that has been absorbed into the brain. In addition, nothing is
known about the mechanism of transport of JTP-4819 across the BBB, i.e. it  is  not  known
whether it is transported passively, or is it a substrate of an active transport protein. If it is a
transporter substrate, the translation from rat to human is further complicated, because the
transporters have different characteristics across species (Syvänen et al., 2009).
There  is  also  another  limitation  with  the  current  PK-PD  model.  It  is  based  on  a  single
high-dose drug administration and this may overestimate the EC50 value due to missing
low brain and plasma drug concentrations and the corresponding brain activity data. To
confirm the EC50 values of JTP-4819 and KYP-2047, the study should be repeated with lower
doses and longer follow-up times.
As a summary of the brain PK properties of JTP-4819 and KYP-2047, neither of the model
compounds could readily penetrate the brain, as indicated by the unbound brain/blood
AUC ratios between 0.09 and 0.14, and the total brain/blood ratios of 0.034 and 0.045,
respectively. The unbound brain/blood ratios of JTP-4819 and KYP-2047 were in the same
range as previously reported for low brain penetrating drugs such as atenolol and
entacapone (Hakkarainen et al. 2010). The result is in line with the physicochemical
properties of the PREP inhibitors that do not support extensive brain penetration. However,
even though the fractions absorbed into the brain were relatively small, pharmacologically
active brain concentrations were achieved with both compounds. KYP-2047 was able to
better reach and inhibit the intracellular target enzyme, and the brain concentrations of
KYP-2047 were similar in each brain area investigated. Thus, the PK properties of KYP-2047
can be considered as being more favorable than those of JTP-4819 and it may be better
suited for use in the characterization of PREP as a CNS drug target.
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6.2 PHARMACODYNAMIC STUDIES
6.2.1 Inhibition of brain PREP
The effect of JTP-4819 on brain PREP activity has been previously studied ex vivo in rats.
JTP-4819 (3 mg/kg p.o. = 8.3 μmol/kg) produced 26-43% PREP inhibition in various brain
areas at 1 h after administration and 35-50% inhibition at 3 h after administration (Toide et
al., 1995a). Based on this data, practically all preclinical PD studies with JTP-4819 in rodents
have been carried out using doses between 0.1-10 mg/kg (0.28-28 μmol/kg) p.o. (I).
At a dose of 9 μmol/kg i.p., KYP-2047 has been reported to inhibit rat brain PREP by 85-
45 % for 6 h ex vivo (Venäläinen et al., 2006). However, it should be noted that both Toide
and Venäläinen used unperfused brain tissue in their experiments (see discussion below).
The present results reveal that KYP-2047 produces a higher degree of brain PREP
inhibition than JTP-4819 at an equimolar single dose. In KYP-2047 treated animals, the
brain PREP activity was fully inhibited 10-60 min after administration, whereas JTP-4819
did not produce such complete inhibition of brain PREP activity at any time point.
The lower degree and greater variation of PREP inhibition achieved by JTP-4819 may be
explained  by  the  PK  properties  of  this  drug.  The in vitro permeability data clearly
demonstrated that the cell permeation properties of JTP-4819 are poor. In the in vivo
studies, JTP-4819 was shown to have almost similar unbound extracellular brain/blood
ratios than KYP-2047, but the comparison between the total brain tissue concentrations and
the unbound extracellular concentrations suggested that JTP-4819 had been trapped
unbound within the extracellular compartment, and could not easily pass the neuronal cell
membranes to reach the intracellular PREP. In contrast, KYP-2047 was able to distribute
from the ECF into the intracellular compartment, and it inhibited PREP more efficiently.
To  the  best  of  our  knowledge,  this  is  the  first  study  where  the  degree  of  brain  PREP
inhibition has been measured from perfused brain tissue. With this approach, it is possible
to avoid the problems associated with the residual blood remaining in the brain capillaries
at the time of the decapitation (Figure 17). If one wishes to obtain reliable brain tissue drug
levels, the residual blood should always be removed. The importance of the blood removal
can be demonstrated by a simple calculation. The total arterial and venous blood volume in
the brain of a 250 g rat has been estimated to be approximately 5% of its total 1.2 ml brain
tissue volume (Davies and Morris, 1993; Duong and Kim, 2000; Liu et al., 2005). Thus, the
physiological volume of intravascular space and blood in the rat brain can be calculated
with the Equation 4
V(blood, brain)= 0.05 × 1.2 ml = 0.06 ml Eq. 4
The amount of drug (n) in the brain vasculature at the maximal brain concentration (Cmax)
can be calculated with the Equation 5
n= Cmax × V(blood, brain) Eq. 5
For example, in the case of JTP-4819, n= 79 μmol/l × 0.00006 l = 4.74 nmol. At the same time,
the total concentration of JTP-4819 in the bloodless brain tissue was measured as being 1.47
μM. If one assumes that JTP-4819 was distributed equally to the nonvascular brain volume
(1.20 ml-0.06 ml= 1.14 ml), then the amount of drug that had passed through the BBB and
distributed into the brain was 0.00114 l × 1.47 μmol/l = 1.68 nmol. This indicates that there
would have been a 3-fold higher amount of JTP-4819 in the brain vasculature than in the
brain tissue at the time of the sample collection.
Earlier ex vivo studies  with  PREP  inhibitors  have  assayed  the  enzyme  activity  without
removing  the  residual  blood  from  the  brain.  On  the  basis  of  above  calculation,  it  is  clear
that the drug in the brain vasculature could affect the enzyme activity measurement if it
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were to be homogenized together with the brain. For example, JTP-4819 at 3 mg/kg
produced not more than 50% brain PREP inhibition ex vivo (Toide et al., 1995a), although
the cerebral blood contaminated the assay. This raises the question of to what degree the rat
brain  PREP  has  been  inhibited  in  many  PD  studies  with  JTP-4819  at  the  most  commonly
used doses which have ranged from 0.1-3 mg/kg (Tables 1 and 3), when the degree of
inhibition in bloodless brain at a dose of 50 μmol/kg (~18 mg/kg) was maximally 85%
(Figure 10). Hence, it is difficult to estimate to what extent the previously reported effects of
JTP-4819  in  the  PD  studies  were  truly  attributable  to  brain  PREP  inhibition.  It  is  also
possible that these effects are a result of an off-target effect, which may regulate other
pathways than the originally targeted PREP.
6.2.2 Effect of KYP-2047 on spatial memory
Most PREP inhibitors were originally designed as antiamnesic drug candidates acting by
elevating memory associated neuropeptides. Currently, there is a consensus that PREP
inhibitors may have some positive effects on learning and memory (summarized in Table 3
and I).
Thus  far,  the  only  PREP  inhibitor  tested  in  the  Morris  water  maze  is  JTP-4819.  In  this
model, JTP-4819 has shown positive cognitive effects in aged rats and rats with middle
cerebral artery occlusion or ibotenate lesion of nucleus basalis magnocellularis (I). These
effects have been suggested to be mediated through reduced breakdown of proamnesic
neuropeptides, such as SP and TRH by PREP, or through elevated levels of ACh. However,
the cognitive effects were neither dose-dependent nor robust.
In the present study, the effect of KYP-2047 on scopolamine induced amnesia was tested
in young and old rats in Morris water maze. In young rats, KYP-2047 showed some
beneficial effects at a dose of 15 μmol/kg, but not at a dose of 3 μmol/kg. It is unlikely that
the brain PREP was significantly inhibited at 3 μmol/kg. In old rats, the effect of KYP-2047
(15 μmol/kg) on scopolamine-amnesia was negligible. In contrast to the working
hypothesis, the disruptive effects of scopolamine were weak in the old rats, thus
complicating the interpretation of KYP-2047 -induced effects. Because of the poor
scopolamine-response, the study should be repeated with a higher scopolamine dose. Also
the dose of KYP-2047 could be higher to ensure a high degree of brain PREP inhibition
during the trials.
The mechanism of action behind the positive cognitive effects in young rats remained
unclear.  The  neuropeptide  and  IP3 assays did not produce any evidence that the effects
would have been mediated through elevated levels of SP, NT, or IP3. Furthermore, our data
on  extracellular  ACh  levels  showed  that  PREP  inhibitors  tend  to  decrease  rather  than
increase striatal ACh levels (see chapter 6.2.5), indicating that the positive effects on
cognition are not likely to be mediated through enhanced cholinergic system as
hypothesized earlier (Toide et al., 1995a). However, we did not measure ACh levels in the
hippocampus or cortex, which are generally considered to be the most important brain
areas in terms of spatial learning and memory (see Deiana et al., 2011; Graef et al., 2011;
Micheau and Marighetto, 2011). On the other hand, the striatal cholinergic system has an
important interaction with the hippocampal cholinergic system e.g. in place and response
learning (Chang and Gold, 2003; Pych et al., 2005a; Pych et al., 2005b). It is also unlikely that
the  DAergic  system  would  be  involved  in  the  cognition-enhancing  effects  of  PREP
inhibitors (see chapter 6.2.6).
Taken together, this study confirmed the earlier findings that PREP inhibitors may have
some positive effects on cognition. KYP-2047 may possess some potential as a cognitive
enhancer, although it is disappointing that the positive behavioral effect was observed only
in young rats. Further experimental investigations will be needed to clarify the mechanism
of action of the cognitive effects.
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6.2.3 Neuropeptide levels
The effect  of  PREP inhibition on the  neuropeptide levels  in  rat  brain  was studied from
tissue extracts (III) and microdialysates (IV). The difference between these experiments is
that the microdialysate peptide levels reflect the situation in the extracellular space close to
the target receptors of neuropeptides, whereas the total tissue extracts give an estimate of
both the intracellular and extracellular peptide contents in the brain. The total tissue
peptide  samples  are  also  subjected  to post-mortem unspecific proteolysis, whereas the
microdialysate is considered to be free of peptidase activity. For these reasons, the
microdialysis peptide levels reflect the physiological situation more reliably than the total
tissue levels.
The changes in the total tissue neuropeptide levels have been assessed with a number of
PREP inhibitors, with perhaps JTP-4819 being the most widely studied (see I). Increased
neuropeptide levels after JTP-4819 treatment have been described under various conditions,
but the results are far from convincing. Also in the present study, JTP-4819 had no effect on
either the total (III) or extracellular (IV) NT or SP levels in various brain areas. These
findings are in agreement with many previous studies, where JTP-4819 has failed to
increase peptide levels in the brain. In rats with middle cerebral artery occlusion, repeated
administration of JTP-4819 (0.1-3 mg/kg, p.o. = 0.28-8.3 μmol/kg) did not affect the cortical
or hippocampal SP levels (Shinoda et al., 1996). Furthermore, negative results were
reported on the SP levels of the brains of aged rats after a single dose treatment with JTP-
4819 (0.3-3 mg/kg) (Toide et al., 1995b). There are no earlier reports on the effects of JTP-
4819 on brain NT levels.
In addition, the effects of JTP-4819 on the levels of other putative PREP substrates are
conflicting, and the effects are seldom dose-dependent. A single dose of JTP-4819 (1-3
mg/kg p.o.) failed to increase the cortical levels of TRH (Toide et al., 1996). Furthermore,
single or repeated administrations of JTP-4819 (1-3 mg/kg p.o.) had no effect on the AVP
levels in the brains of aged rats (Toide et al., 1995b) or rats with middle cerebral artery
occlusion (Shinoda et al., 1996).
One explanation for the above conflicting peptide results might be that the observed
changes in the peptide levels are at least partly a result of unspecific proteolysis occurring
during sample collection and preparation. Non-specific peptide degradation occurs rapidly
after death leading to unphysiological changes in the peptide contents of the samples
(Tenorio-Laranga et al., 2009). Furthermore, the interaction between the enzyme, inhibitor
and the substrate may occur only in the brain homogenate ex vivo, but not in the true in vivo
situation where the cellular compartments are intact, and the peptides released into the
synaptic cleft are not accessible to the intracellularly located PREP.
 Interestingly, when elevated peptide levels have been reported after JTP-4819
administration, the effects have generally been better in the cortex than in the hippocampus
(Table 1). This might be partly explained by the higher JTP-4819 concentrations observed in
the cortex (Table 5). For example, repeated administration of JTP-4819 (0.3-3 mg/kg p.o.
once a day for 15 days) reversed the middle cerebral artery occlusion-induced decrease in
TRH levels in the cortex but not in the hippocampus, and a single dose of 3 mg/kg p.o.
could restore the age-related decrease in the SP content in the cortex but not in the
hippocampus of old rats. In addition to neuropeptides, ACh release was found to be almost
2-fold higher in the cortex than in the hippocampus of young rats (Toide et al. 1995a).
The effects of JTP-4819 on extracellular peptide levels are unknown; there are no
published results from microdialysis studies. However, in the review article of Toide et al.
(1998) there is a statement that JTP-4819 (1000 μM at 0.5 μl/min for 2h) administered by
retrodialysis via the microdialysis probe increased synaptic TRH levels in hippocampus and
cortex, suggesting that JTP-4819 modulates TRH levels in the synaptic cleft. However, the
TRH content was measured from the total tissue sample, not from the extracellular space.
Furthermore, the dose used in the retrodialysis is extremely high and would be impossible
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to reach after systemic administration; the periprobe extracellular concentrations have been
probably 200-300 times higher than the peak concentrations (around 1.5 μM) measured
after the i.p. administration of 50 μmol/kg (II).
In the present study, we have shown that KYP-2047 at a dose that produces extensive
(100-60%) PREP inhibition in the rat brain (II) has no effect on the total tissue or
extracellular levels of SP or NT in the rat brain (III, IV). Thus, this study did not reveal any
evidence for the involvement of PREP in the digestion of SP or NT. Our extracellular data
on unchanged peptide levels support the concept that the direct regulation of peptide
processing by PREP is not likely due to the discrepancy in the localization of the peptides
and the enzyme. The paradox in the neuropeptide theory suggesting that PREP regulates
neuropeptide levels is that the putative peptide substrates of PREP are released and
metabolized in the synaptic cleft (see Harrison and Geppetti, 2001; St-Gelais et al., 2006),
whereas PREP is known to be located mainly intracellularly. A membrane-bound and less
active form of PREP (mPREP) has also been characterized, but there is no evidence that
mPREP is accessible from the synaptic cleft and its role in the extracellular metabolism of
neuropeptides is unknown (Tenorio-Laranga et al., 2008). It is also known that a number of
peptidases other than PREP are involved in the cleavage of SP and NT (see Harrison and
Geppetti, 2001; St-Gelais et al., 2006). Therefore, the inhibition of PREP alone is not likely to
elevate significantly the levels of these peptides.
Since the involvement of PREP in the extracellular cleavage of neuropeptides seems
unlikely, it is tempting to speculate how PREP could regulate intracellular peptide
signalling. For example, some putative PREP substrates, notably substance P, act as co-
transmitters and are packed into storage vesicles and released together with other
transmitters such as neurokinin A or gamma-aminobutyric acid (GABA) (see Hökfelt et al.,
2001). These vesicles are not absolutely safe against peptidases, since for example
monoamine oxidase (MAO) is an important intracellular metabolizing enzyme although its
substrates are stored in vesicles. Hypothetically, if the substrate is moving, being released
or taken up, it may encounter PREP. In addition, there is some evidence that putative PREP
substrates are involved in the intracrine systems. Intracrines are molecules that have
extracellular signalling functions but also have intracellular actions in the cell in which they
were synthesized (Re and Cook, 2006). For example, a putative PREP substrate, NT, may
have such an action (Toy-Miou-Leong et al., 2004). Interestingly, intracrines have been
associated with long-term potentiation (LTP) and memory. It could be hypothesized that
PREP  is  located  sufficiently  close  to  these  intracellularly  acting  peptides  and  might  be
involved in the intracellular termination of their intracrine effects. However, there is no
experimental data to support this speculation.
6.2.4 IP3 levels
IP3 is a second messenger that is known to be involved in the generation of LTP and
long-term depression (LTD), phenomena that are important in the learning and memory
processes via the release of Ca2+ within the cell (Khodakhah and Armstrong, 1997; Taufiq et
al., 2005).
Several lines of investigation point to a role for PREP in the regulation of intracellular IP3
levels (see chapter 2.1.5). The mutated social amoeba Dictyostelium discoideum missing the
Prep gene  (DpoA  mutant)  was  resistant  to  the  inositol  and  IP3 depleting effect of lithium
(Williams et al., 1999), and the same effect was seen in wild type Dictyostelium after
enzymatic inhibition of PREP. Schulz et al. (2002) observed that there was an inverse
correlation between the IP3 concentration and PREP expression in mammalian neuronal
cells. In primary neurons, lithium mediated growth cone spreading was reversed by PREP
inhibition (Williams et al., 2002). Furthermore, PREP and IP3 type 1 receptor were highly
colocalized in distinct areas of rat brain (Myöhänen et al., 2008c).
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This is the first study to assess the effect of PREP inhibition on the IP3 levels in vivo. The
IP3 levels were determined in the rat cortex and hippocampus after a 2.5-day treatment
with JTP-4819. No effect was seen, and thus, this study did not produce any evidence for
the involvement of PREP in the regulation of IP3 levels in vivo.  One  explanation  for  this
result may be that the degree of brain PREP inhibition at the dose of 9 μmol/kg b.i.d was
not sufficient to influence the IP3 regulatory pathway. The lack of effect might be explained
by a technical aspect as well; since only a fraction of cells in the brain contain PREP, the IP3
elevating effect is lost once the brain tissue is homogenized and diluted with assay buffer.
Therefore, even important changes in the IP3 levels of the PREP containing cells may not be
detected. Another and perhaps a more sensitive approach to study the effects of PREP
inhibition on IP3 levels in vivo would be to measure the changes in the intracellular Ca2+
release, which is the physiological cellular response that IP3 triggers.
6.2.5 ACh levels
ACh is a key transmitter in cognitive processes (see Deiana et al., 2011; Graef et al., 2011;
Micheau and Marighetto, 2011) and many biologically active PREP substrates have been
associated with cholinergic transmission. For example, TRH (Toide et al., 1993) and SP
(Vlasova and Dolgopol'skii, 2000; Perez et al., 2007) have been shown to increase ACh
efflux in the brain. However, little is known about the effects of PREP inhibitors on brain
ACh levels.  The only  study that  has  reported the  effect  of  PREP inhibition on brain  ACh
levels was conducted by Toide et al. (1995a); JTP-4819 (1 or 3 mg/kg p.o.) significantly but
not dose-dependently increased extracellular ACh levels in the frontal cortex (by ~160%)
and hippocampus (by ~90%) of young rats, but in 24 month old rats, the effect was weaker
(~40% increase). The authors hypothesized that JTP-4819 increased the brain levels of SP,
TRH  or  AVP  and  in  this  way  increased  ACh  release,  but this mechanism has not been
confirmed. Surprisingly, other PREP inhibitors have not been tested for their ability to
modulate brain ACh levels.
Other  reports  have  found  only  indirect  evidence  on  the  involvement  of  PREP  in  the
cholinergic system. Another PREP inhibitor, Y-29794, was reported to potentiate TRH
induced ACh release in the hippocampus of rat brain in a microdialysis study, suggesting
that ACh release had been caused by increased TRH levels (Nakajima et al., 1992). In old
rats, a 3-week treatment with JTP-4819 (1 or 3 mg/kg p.o.) reversed the age-related increase
in choline acetyltransferase (ChAT) activity in cortex and also the decrease of choline
uptake in the hippocampus (Toide et al., 1997), suggesting that JTP-4819 may have reversed
age-related cholinergic dysfunction.
The  present  study  was  designed  to  assess  the  effect  of  PREP  inhibitors  on  the  striatal
ACh and DA (see chapter 6.2.6) levels (V). Striatum was selected as the target tissue for the
following reasons. Firstly, the cholinergic system in the striatum is involved in a diverse set
of cognitive functions through interactions with other neurotransmitter systems such as the
dopaminergic system (see Havekes et al., 2011). Secondly, there is emerging evidence from
different behavioral tasks suggesting that the striatal cholinergic system undergoes
important interactions with the hippocampal cholinergic system e.g. in place and response
learning (Chang and Gold, 2003; Pych et al., 2005a; Pych et al., 2005b), and PREP has been
associated with these functions. Thirdly, endogenously produced ACh in the striatum is
crucial for the induction of corticostriatal LTP (Calabresi et al., 1999). Fourthly, ACh and
DA are known to regulate each other’s release in striatum (Abercrombie and DeBoer, 1997,
Brady et al., 2008, Jeon et al., 2010, Lehmann and Langer, 1983, Millan et al., 2004, Smolders
et al., 1997, Threlfell et al., 2010). Finally, PREP protein is widely expressed in the striatum
and PREP has been reported to colocalize with striatal ACh (Myöhänen et al. 2008a)
suggesting an interaction between ACh and PREP.
In the present study, both JTP-4819 and KYP-2047 decreased extracellular ACh levels.
This does not support the earlier hypothesis suggesting that the positive effects of PREP
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inhibitors on cognition would be mediated through elevated ACh levels. JTP-4819
decreased ACh both after systemic and intrastriatal administration, whereas KYP-2047 had
an effect only after the intrastriatal administration. This difference may be attributable to
the different PK characteristics of these molecules (II).
The ACh results in this study contradict the findings of the only earlier microdialysis
study on the effects of PREP inhibition on brain ACh levels (Toide et al., 1995a). The
difference may be explained by a number of factors. Firstly, different brain areas were
investigated. Secondly, the doses used in the present study have been proven to inhibit
PREP by at least 60-80% for 5 h. Most importantly, Toide and co-workers used an extremely
high concentration (10 μM) of the AChE inhibitor physostigmine in the perfusate in order
to obtain detectable quantities of ACh, and this could well have influenced the basal ACh
release (Messamore et al., 1993). The ACh levels here were determined in the presence of
100 nM neostigmine, which is not believed to affect basal ACh release (Himmelheber et al.,
1998; Kehr et al., 2010). It has even been postulated that the addition of low-concentration
neostigmine is necessary for assessing the functional changes in the release of ACh (Chang
et al., 2006).
On  the  basis  of  the  current  knowledge,  it  is  difficult  to  attribute  the  decrease  in  ACh
levels after JTP-4819 and KYP-2047 administration to the inhibition of PREP peptidase
activity. Firstly, recent studies have found no evidence that PREP would regulate the brain
levels of peptides (e.g. SP, TRH or AVP) that are associated with the regulation of ACh
release (III, IV, Brandt et al., 2005; Nolte et al., 2009; Tenorio-Laranga et al., 2009).
Furthermore, one would expect rather an increase in ACh release if PREP had elevated the
levels of these neuropeptides. Secondly, the degree of brain PREP inhibition by JTP-4819
and KYP-2047 and the observed effect on ACh levels are not parallel; both compounds are
known to inhibit brain PREP by 80-100% within 10-30 min after a single dose of 50 μmol/kg
i.p. (II).  In  the  present  study,  however,  only  JTP-4819  decreased  ACh  levels  at  this  dose.
When the compounds were administered directly into the brain by retrodialysis, both PREP
inhibitors rapidly decreased ACh levels. This may be explained by the fact that the maximal
extracellular concentrations in the periprobe tissue have been considerably higher after the
intrastriatal administration than after the systemic administration. In summary, the
decrease in ACh levels did not correlate with the degree of PREP inhibition, and higher
brain drug levels would be needed to modulate ACh release than to inhibit PREP. This may
point to an off-target mechanism for JTP-4819 and KYP-2047, or to a mechanism that is not
related to the catalytic activity of PREP. Indeed, it has been suggested that PREP can
regulate certain intracellular functions via cytosolic protein-protein interactions rather than
via its peptidase activity (Schulz et al., 2005; Di Daniel et al., 2009). PREP inhibitors might
modulate these functions by causing conformational changes in the tertiary structure of the
enzyme and thus perturb the protein-protein interactions (Fuxreiter et al., 2005).
The spatial associations between PREP and ACh do not support a role for PREP in the
regulation of ACh release (Myöhänen et al., 2008a; Peltonen et al., 2011).
Immunohistochemical studies have shown that the colocalization of PREP protein and ACh
in the brain is rather low. Moreover, the ACh synthesizing enzyme ChAT is only partially
colocalized with PREP in the cortex, but not in the hippocampus or medial septum. In
striatum, the colocalization of PREP with cholinergic neurons is poor (Myöhänen et al.,
2008a). This further supports the present findings indicating that the effects of JTP-4819 and
KYP-2047 on the striatal ACh levels are not mediated by inhibition of PREP catalytic
activity.
In  an  attempt  to  find  some  clues  to  the  possible  mechanisms  that  could  explain  the
decreased ACh levels, an in vitro pharmacological profiling was performed for JTP-4819
and KYP-2047 (V). This analysis of 70 pharmacological targets did not reveal any obvious
off-targets that could account for the effect on ACh levels. Furthermore, JTP-4819 and KYP-
2047 did not exert any inhibitory effect on several serine proteases and proline-specific
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proteases in vitro at 10 μM concentration (V). Slight inhibition of lysosomal prolyl
carboxypeptidase was observed at 10 μM, which is 1000-fold higher concentration than that
needed to fully inhibit PREP in vitro. As far as we are aware, prolyl carboxypeptidase has
not  been  associated  with  the  regulation  of  ACh  levels  in  the  brain.  Overall,  these  results
validate the proposal that JTP-4819 and KYP-2047 have a high selectivity towards PREP.
In humans plasma AChE activity has been observed to gradually increase after multiple
doses of JTP-4819 (Umemura et al., 1997). Theoretically, if this increase holds true in the
brain after a single dose as well, it could explain the decrease in the extracellular ACh
levels. The in vitro screen showed that there was no significant interaction between JTP-
4819 or KYP-2047 and AChE, i.e. the increase in the AChE activity would appear to be
mediated through an indirect mechanism. A further study could assess the effect of PREP
inhibitors on the AChE activity in the rat brain in vivo.
One interesting off-target that was not included in the screening is ChAT, an enzyme
which catalyzes the synthesis of ACh from choline and acetyl coenzyme A. Theoretically,
inhibition  of  ChAT  by  PREP  inhibitors  would  decrease  the  synthesis  and  release  of  ACh
and explain the observed effect in ACh levels. Therefore, the effects of PREP inhibitors on
ChAT activity should also be determined.
6.2.6 DA levels
As far as is known, this is the first report on the effects of PREP inhibitors on brain DA
levels. PREP inhibitors had no significant effect on the striatal DA levels; JTP-4819 at doses
of 15 and 50 μmol/kg i.p. and and KYP-2047 at a dose of 50 μmol/kg i.p. tended to decrease
(ns) the levels, but the interindividual variation was high. Moreover, no effect was seen in
DOPAC and HVA levels; only normal the fluctuation related to the circadian rhythm was
observed (Castaneda et al., 2004), which are parallel with the minor changes in the DA
levels.
Although  DA  and  ACh  systems  exist  in  close  proximity  in  the  striatum,  the  minor
change seen in  DAergic  transmission is  most  unlikely  to  explain  the  observed changes  in
the ACh levels. This result is consistent with immunohistochemical studies indicating that
PREP is not present in the DAergic neurons in the striatum (Myöhänen et al., 2008a).
Furthermore, destruction of DAergic neurons in the medial forebrain bundle with 6-
hydroxydopamine had no effect on the PREP activity or immunoreactivity in the striatum,
which is the terminal projection area of these DAergic neurons (Peltonen et al., 2011). NT, a
PREP substrate in vitro, is known to regulate DA release in the brain (see St-Gelais et al.,
2006), but our studies have shown that PREP inhibitors have no effect on either the total
brain tissue or on the extracellular NT levels (III, IV).
In summary, current evidence points to no role for PREP inhibitors in the modulation of
the DAergic system. Thus, the positive cognitive effects of PREP inhibitors are not likely to
be mediated through this system. On the other hand, the lack of DAergic effect in the
striatum suggests that PREP inhibitors do not have the potential to induce extrapyramidal
side effects.
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7 Summary and conclusions
Despite intensive research, the main physiological function and the general potential of
PREP as a drug target remains obscure. No specific indication for the therapeutic use of
PREP inhibitors has yet been found. Therefore, further studies are required to elucidate the
physiological  role  of  PREP  both  in  the  CNS  and  in  the  periphery,  and  to  validate  the
pharmacological effects of PREP inhibitors.
The  major  findings  of  this  study  and  their  impact  on  the  current  understanding  about
PREP as a target for drug development have been summarized in Table 6. The present
study aimed to characterize the PK and PD properties of two model PREP inhibitors, JTP-
4819 and KYP-2047, in the rat. This is the first study to assess the brain pharmacokinetics of
PREP inhibitors. It was shown that the model inhibitors were able to penetrate the brain in
pharmacologically active concentrations.
The behavioral study confirmed the earlier findings that PREP inhibitors have some
potential  as  cognitive  enhancers,  but  the  PD  studies  could  not  elucidate  any  specific
mechanism of action for this effect. As long as the proof of mechanism is unknown, the
potential of PREP inhibitors as memory enhancing drugs remains unconvincing.
This study provides novel information on the lack of effect of PREP inhibition on
extracellular neuropeptide levels. Together with other recent findings, this result suggests
that PREP is not involved in the extracellular cleavage of proline-containing peptides. This
seems rational since the enzyme is located intracellularly and peptide cleavage occurs
mainly  extracellularly.  A  novel  finding  was  also  that  PREP  inhibitors  were  found  to
decrease the extracellular ACh levels in the rat striatum by some unknown mechanism.
Based on the results of the experimental section (II-V), the following specific conclusions
can be drawn:
1. The model PREP inhibitors have different PK properties in the rat. KYP-2047 penetrates
the brain better than JTP-4819, distributes homogenously in the brain, and inhibits brain
PREP more efficiently after systemic administration of a single dose. This may be due to
the poor ability of JTP-4819 to permeate through the cell membranes and to reach the
intracellular PREP. KYP-2047 is a highly potent, brain penetrating, PREP specific
inhibitor and it represents a suitable pharmacological tool to assess the potential of
PREP as a drug target.
2. KYP-2047 has a positive effect on spatial learning in young rats in the Morris water
maze. This confirms previous findings on the positive effects of PREP inhibitors on
cognition. However, the mechanism of action remains unknown despite the fact that
several potential mechanisms were investigated in vivo using the model inhibitors, JTP-
4819 and KYP-2047. The high degree of PREP inhibition had no effect on the brain levels
of memory enhancing neuropeptides NT or SP, failed to increase brain IP3 levels,  and
had no significant effect on striatal DA levels.
3. JTP-4819 and KYP-2047 decrease the extracellular levels of striatal ACh by some
unknown mechanism. However, the decrease does not seem to be attributable to the
degree of PREP inhibition.
4. The lack of effect of PREP inhibitors on extracellular peptide levels and the known
intracellular localization of PREP indicate that rather than being involved in the
extracellular cleavage of proline-containing peptides, PREP may be a part of some
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intracellular protein machinery e.g. as a component of the proteasome degradation
pathway.
5. On  the  basis  of  recent  findings,  it  seems  that  the  most  promising  sources  for  future
research involve clarifying the roles of PREP in neutrophil mediated inflammation, in -
synuclein aggregation and in cell proliferation and differentiation. The present findings
provide  the  following  targets  for  future  research:  the  effect  of  PREP  inhibition  on  the
brain levels of other neurotransmitters known to be involved in cognitive processes,
such as glutamate, serotonin, GABA and noradrenaline, should be determined.
Furthermore,  the  effects  of  PREP  inhibitors  on  ACh  levels  as  well  as  on  AChE  and
ChAT  activities  in  other  brain  areas  (e.g. the hippocampus and cortex) should be
assessed. Finally, if one wishes to establish a link between IP3 and PREP in vivo, a future
study could assess  the  effect  of  PREP inhibition on the  intracellular  Ca2+ release in the
brain.
Table 6: A summary of the major findings of the present study and their impact on the current
understanding about PREP as a drug target.
Measure JTP-
4819
KYP-
2047
Impact of the finding(s)
Brain
penetration
+ ++ The general potential of current PREP inhibitors to penetrate the
BBB and reach the CNS target site is relatively poor.
Brain PREP
inhibition
+ ++ KYP-2047 is a suitable pharmacological tool to assess the potential
of PREP as a CNS drug target.
Spatial
memory
NA + Young
± Old
Confirms earlier findings on the positive effects of PREP inhibitors
on learning and memory.
Whole tissue
neuropeptide
levels
± ± Questions the role of PREP in cleavage of neuropeptides in vivo;
regulation of the brain levels of classical PREP substrates by PREP
inhibitors is unlikely.
IP3 ± NA PREP inhibition has no major role in controlling the brain levels of
IP3 in vivo.
Extracellular
neuropeptide
levels
NA ± Questions the role of PREP in cleavage of neuropeptides in vivo.
Indicates that PREP as an intracellular enzyme cannot affect the
extracellular cleavage of neuropeptides.
Extracellular
ACh levels
  Contradicts the earlier findings on the elevating effects of PREP
inhibition on brain ACh levels. The positive cognitive effects of PREP
inhibitors are not likely to be mediated by increased ACh levels.
Extracellular
DA levels
± ± PREP inhibition has no major role in modulating the striatal DA
levels.
In vitro
selectivity
± ± Both model inhibitors have a high selectivity towards PREP.
+, positive finding; ±, no change in measure; , negative finding; NA, not assessed.
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Prolyl oligopeptidase (PREP) cleaves 
proline containing small peptides 
such as substance P and neurotensin. 
PREP is an abundant peptidase in 
the mammalian brain and periphery, 
but the physiological role of PREP 
remains unknown. This dissertation 
aims at characterizing the pharma-
cokinetic and pharmacodynamic 
properties of specific PREP inhibitors 
in the rat. It provides new perspec-
tives into the physiological role of 
PREP and evaluates the importance 
of PREP as a drug target.
